[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 705
1. Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Kawamura T, Obara S, Tanaka J, Asaka M, Imamura M, Masauzi N: Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3). Med Hypotheses; 2006;66(1):201-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3).
  • [MeSH-major] Arsenicals / adverse effects. Arsenicals / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration / chemically induced. Lung / pathology. Oxides / adverse effects. Oxides / therapeutic use

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16165312.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Deltaretrovirus Antibodies; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


2. Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ: Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem Biophys Res Commun; 2006 Feb 10;340(2):359-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia.
  • Adult T cell leukemia is an aggressive and frequently fatal malignancy that expressess constitutively activated growth-signaling pathways in association with deregulated growth and resistance to apoptosis.
  • But the effect and mechanism of action of curcumin on T cell leukemia is not known.
  • To investigate the antitumor activity of curcumin in T cell leukemia, we examined its effect on constitutive phosphorylation of JAK and STAT proteins, proliferation, and apoptosis in HTLV-I-transformed T cell lines.
  • HTLV-I-transformed T cell leukemia lines, MT-2, HuT-102, and SLB-1, express constitutively phosphorylated JAK3, TYK2, STAT3, and STAT5 signaling proteins.
  • In vitro treatment with curcumin induced a dose-dependent decrease in JAK and STAT phosphorylation resulting in the induction of growth-arrest and apoptosis in T cell leukemia.
  • The induction of growth-arrest and apoptosis in association with the blockade of constitutively active JAK-STAT pathway suggests this be a mechanism by which curcumin induces antitumor activity in T cell leukemia.
  • [MeSH-major] Apoptosis / drug effects. Curcumin / pharmacology. Growth Inhibitors / pharmacology. JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors. Leukemia, T-Cell / enzymology. Leukemia, T-Cell / pathology. MAP Kinase Signaling System / drug effects. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Humans. Janus Kinase 3. Phosphorylation / drug effects. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / biosynthesis. Protein-Tyrosine Kinases / genetics. STAT3 Transcription Factor / antagonists & inhibitors. STAT3 Transcription Factor / biosynthesis. STAT3 Transcription Factor / genetics. STAT5 Transcription Factor / antagonists & inhibitors. STAT5 Transcription Factor / biosynthesis. STAT5 Transcription Factor / genetics. TYK2 Kinase

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364242.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R21CA106207-01; United States / NINDS NIH HHS / NS / R01 NS42257-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Growth Inhibitors; 0 / JAK3 protein, human; 0 / Protein Kinase Inhibitors; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinase 3; EC 2.7.10.2 / TYK2 Kinase; EC 2.7.10.2 / TYK2 protein, human; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; IT942ZTH98 / Curcumin
  •  go-up   go-down


3. Yamamoto B, Li M, Kesic M, Younis I, Lairmore MD, Green PL: Human T-cell leukemia virus type 2 post-transcriptional control protein p28 is required for viral infectivity and persistence in vivo. Retrovirology; 2008 May 12;5:38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type 2 post-transcriptional control protein p28 is required for viral infectivity and persistence in vivo.
  • BACKGROUND: Human T-cell leukemia virus (HTLV) type 1 and type 2 are related but distinct pathogenic complex retroviruses.
  • HTLV-1 is associated with adult T-cell leukemia and a variety of immune-mediated disorders including the chronic neurological disease termed HTLV-1-associated myelopathy/tropical spastic paraparesis.
  • In contrast, HTLV-2 displays distinct biological differences and is much less pathogenic, with only a few reported cases of leukemia and neurological disease associated with infection.
  • CONCLUSION: We provide direct evidence that p28 is dispensable for viral replication and cellular immortalization of primary T-lymphocytes in cell culture.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Mar;74(6):2655-62 [10684280.001]
  • [Cites] N Engl J Med. 2000 Mar 30;342(13):930-6 [10738051.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11852-7 [10766811.001]
  • [Cites] J Virol. 2000 Dec;74(23):11270-7 [11070026.001]
  • [Cites] J Virol. 2001 Sep;75(18):8440-8 [11507189.001]
  • [Cites] J Virol. 2001 Oct;75(20):9885-95 [11559821.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] J Virol. 2004 Oct;78(20):11077-83 [15452228.001]
  • [Cites] Nature. 1983 Oct 6-12;305(5934):502-5 [6312323.001]
  • [Cites] Science. 1985 Aug 16;229(4714):675-9 [2992082.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):571-4 [2999613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] Blood. 1988 Feb;71(2):363-9 [2827811.001]
  • [Cites] Nature. 1988 Jun 23;333(6175):776-8 [2838755.001]
  • [Cites] J Virol. 1990 Oct;64(10):4914-21 [2398533.001]
  • [Cites] Neurology. 1991 Jan;41(1):85-7 [1985300.001]
  • [Cites] J Virol. 1991 Aug;65(8):4408-13 [2072457.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):645-6 [1347339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8813-7 [1528897.001]
  • [Cites] Ann Neurol. 1993 Apr;33(4):411-4 [8489213.001]
  • [Cites] J Virol. 1995 Jan;69(1):387-94 [7983733.001]
  • [Cites] Virology. 1995 Jun 1;209(2):445-56 [7539968.001]
  • [Cites] J Virol. 1995 Oct;69(10):6297-303 [7666530.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1030-5 [8562927.001]
  • [Cites] J Virol. 1997 Feb;71(2):1181-90 [8995640.001]
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] J Virol. 1998 May;72(5):4458-62 [9557741.001]
  • [Cites] J Virol. 1998 Nov;72(11):8852-60 [9765430.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):8112-9 [10482560.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:620-42 [15569604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(14):6178-98 [15988028.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5926-30 [16155599.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] J Virol. 2005 Dec;79(23):14536-45 [16282453.001]
  • [Cites] J Virol. 2006 Jan;80(1):181-91 [16352542.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1980-8 [16263794.001]
  • [Cites] Blood. 2006 May 15;107(10):3976-82 [16424388.001]
  • [Cites] Virology. 2006 Oct 25;354(2):225-39 [16890266.001]
  • [Cites] J Virol Methods. 2007 Jun;142(1-2):159-68 [17337070.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14608-15 [17360706.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • (PMID = 18474092.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100730-06; United States / NCI NIH HHS / CA / P01 CA100730; United States / NCI NIH HHS / CA / CA100730; United States / NCI NIH HHS / CA / P01 CA100730-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Gene Products, tax; 0 / Retroviridae Proteins; 0 / Viral Proteins; 0 / tax protein, Human T-lymphotrophic virus 2
  • [Other-IDs] NLM/ PMC2405800
  •  go-up   go-down


Advertisement
4. Murata K, Yamada Y: The state of the art in the pathogenesis of ATL and new potential targets associated with HTLV-1 and ATL. Int Rev Immunol; 2007 Sep-Dec;26(5-6):249-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Almost 30 years have passed since adult T-cell leukemia (ATL) was identified as a new disease entity in Japan.
  • During this period, its causative agent, human T-cell leukemia virus (HTLV-1), was discovered, and a crucial role of the viral product Tax in ATL leukemogenesis was demonstrated.
  • Recently, another HTLV-1 product, HBZ, which is encoded on the negative strand, was found, and it has now become a subject of intensive research because of its possible activity in cell proliferation.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027200.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / CCR4 protein, human; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / NF-kappa B; 0 / Receptors, CCR4; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Viral Proteins
  • [Number-of-references] 90
  •  go-up   go-down


5. Karube K, Suzumiya J, Okamoto M, Takeshita M, Maeda K, Sakaguchi M, Inada T, Tsushima H, Kikuchi M, Ohshima K: Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases. Am J Surg Pathol; 2007 Feb;31(2):216-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell lymphoma/leukemia with angioimmunoblastic T-cell lymphomalike features: Report of 11 cases.
  • In adult T-cell lymphoma/leukemia (ATLL), the neoplastic lymphoid cells are usually medium-sized to large, often with pronounced nuclear pleomorphism compatible with the diagnosis of diffuse pleomorphic peripheral T-cell lymphoma.
  • We describe here 11 patients with the rare morphologic variant of ATLL, angioimmunoblastic T-cell lymphoma (AILT)-like type.
  • All patients were positive for antiadult T-cell leukemia/lymphoma-associated antigen, which is a specific antibody for human T-cell lymphotropic virus type-I.
  • [MeSH-major] Immunoblastic Lymphadenopathy / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Female. HTLV-I Infections / virology. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255766.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / DNA, Viral
  •  go-up   go-down


6. Bellon M, Baydoun HH, Yao Y, Nicot C: HTLV-I Tax-dependent and -independent events associated with immortalization of human primary T lymphocytes. Blood; 2010 Mar 25;115(12):2441-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type I (HTLV-I)-associated malignancies are seen in a small percentage of infected persons.
  • Tax expression was required for the growth of primary T cells, but was not sufficient to propel T cells into cell cycle in the absence of exogenous interleukin-2 (IL-2).
  • We also found disruption of putative tumor suppressors IL-16 and translocated promoter region (TPR) in Tax-immortalized and HTLV-I-transformed cell lines.
  • These data provide a better understanding of Tax functions in human T cells, and highlight the limitations of Tax, suggesting that other viral proteins are key to T-cell transformation and development of adult T-cell leukemia.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1998 Feb;72(2):1165-70 [9445014.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):453-9 [19064971.001]
  • [Cites] Exp Cell Res. 1999 Mar 15;247(2):525-33 [10066380.001]
  • [Cites] J Virol. 1999 May;73(5):3709-17 [10196263.001]
  • [Cites] Oncogene. 1999 Apr 15;18(15):2441-50 [10229195.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] EMBO J. 2006 Apr 19;25(8):1741-52 [16601696.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2090-7 [16786598.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1135-41 [17704807.001]
  • [Cites] Apoptosis. 2008 Jun;13(6):733-47 [18421579.001]
  • [Cites] J Virol. 2008 Sep;82(17):8442-55 [18596104.001]
  • [Cites] Oncogene. 2000 Feb 10;19(6):827-30 [10698501.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8580-9 [11046153.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35926-31 [10931836.001]
  • [Cites] J Immunol. 2001 Apr 15;166(8):4826-30 [11290757.001]
  • [Cites] J Virol. 2002 Apr;76(8):4022-33 [11907241.001]
  • [Cites] J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [12145525.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • [Cites] Blood. 2003 Aug 1;102(3):849-57 [12689947.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3561-71 [15077181.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2523-31 [15226182.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3351-5 [2541443.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):413-7 [2403646.001]
  • [Cites] Science. 1995 Jul 7;269(5220):79-81 [7604283.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1645-52 [8622884.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1607-14 [8612584.001]
  • [Cites] J Virol. 1997 Mar;71(3):1975-83 [9032329.001]
  • [Cites] FEBS Lett. 1997 Apr 14;406(3):263-6 [9136898.001]
  • [Cites] J Virol. 1997 Jun;71(6):4445-51 [9151835.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2946-55 [18511807.001]
  • [Cites] Genes Dev. 2008 Nov 1;22(21):2926-31 [18981471.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3845-50 [9520455.001]
  • (PMID = 20093405.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016475; United States / NCI NIH HHS / CA / R01 CA115398; United States / NCI NIH HHS / CA / CA106258; United States / NCI NIH HHS / CA / CA115398; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Interleukin-2; 0 / tax protein, Human T-lymphotrophic virus 1
  • [Other-IDs] NLM/ PMC2845900
  •  go-up   go-down


7. Lü SQ, Yang JM, Wang JM: [Effects of proteasome inhibitors on leukemias]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):896-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A lot of studies on effects of proteasome inhibitors on leukemias, including plasma cell leukemia; chronic lymphocytic leukemia, adult T cell lymphoma/leukemia, chronic myeloid leukemia and acute myeloid leukemia, were reviewed in this article.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708829.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 27
  •  go-up   go-down


8. Huss R, Renner-Müller I, Buchstaller A: Adult scl+/+ murine hemangioblasts persist in allogeneic mutant blastocysts but fail to rescue the scl-/- phenotype. Stem Cells Dev; 2005 Aug;14(4):402-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult scl+/+ murine hemangioblasts persist in allogeneic mutant blastocysts but fail to rescue the scl-/- phenotype.
  • Isolated and expanded scl (+) adult murine progenitors show a strong endothelial and hematopoietic differentiation potential and have been considered to be the adult equivalent of the hemangioblast.
  • Here, we study the fate of adult scl (+/+) during development and their ability to reverse genetic defects in scl expression. scl (+/+) adult stem cells (clone RM26) did not persist during embryonic development after injection into blastocysts of allogeneic wild-type mice on day E 3.5.
  • [MeSH-minor] Animals. Anoxia. Basic Helix-Loop-Helix Transcription Factors. Blood Cells / cytology. Cell Differentiation. DNA / metabolism. Embryo, Mammalian / metabolism. Gene Expression Regulation, Developmental. Green Fluorescent Proteins / metabolism. Ischemia. Mice. Mice, Inbred BALB C. Mice, Inbred C3H. Phenotype. Stem Cells / cytology. Time Factors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137229.001).
  • [ISSN] 1547-3287
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; 9007-49-2 / DNA
  •  go-up   go-down


9. Wang D, Guo MX, Hu HM, Zhao ZZ, Qiu HL, Shao HJ, Zhu CG, Xue L, Shi YB, Li WX: Human T-cell leukemia virus type 1 oncoprotein tax represses ZNF268 expression through the cAMP-responsive element-binding protein/activating transcription factor pathway. J Biol Chem; 2008 Jun 13;283(24):16299-308
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type 1 oncoprotein tax represses ZNF268 expression through the cAMP-responsive element-binding protein/activating transcription factor pathway.
  • Expression of the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax is correlated with cellular transformation, contributing to the development of adult T-cell leukemia.
  • In this study, we investigated the role of Tax in the regulation of the ZNF268 gene, which plays a role in the differentiation of blood cells and the pathogenesis of leukemia.
  • These findings suggest a role for ZNF268 in aberrant T-cell proliferation observed in HTLV-1-associated diseases.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 1;89(3):1006-10 [1736281.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):981-9 [1402668.001]
  • [Cites] Genes Dev. 1992 Nov;6(11):2066-76 [1427072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):610-4 [8421695.001]
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):14584-90 [8662878.001]
  • [Cites] J Neurovirol. 1997 Feb;3(1):16-27 [9147818.001]
  • [Cites] Virology. 1997 Apr 28;231(1):135-40 [9143312.001]
  • [Cites] Chem Biol. 1995 Dec;2(12):819-26 [8807815.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):7981-7 [10482545.001]
  • [Cites] Int J Mol Med. 2004 Dec;14(6):971-5 [15547661.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:620-42 [15569604.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55127-36 [15496409.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] Int J Mol Med. 2006 Sep;18(3):457-63 [16865230.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24623-36 [16787922.001]
  • [Cites] Mol Endocrinol. 2000 Sep;14(9):1448-61 [10976922.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):928-39 [11154279.001]
  • [Cites] J Virol. 2001 Mar;75(5):2161-73 [11160720.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 16;1518(3):306-10 [11311945.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2123-31 [12200376.001]
  • [Cites] IUBMB Life. 2003 Mar;55(3):127-31 [12822888.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29394-9 [12734192.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Nov;77(11):6815-9 [6256763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Virology. 1985 Nov;147(1):223-6 [2998067.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(3):1071-5 [2300570.001]
  • [Cites] Genes Dev. 1990 Nov;4(11):1875-85 [2276622.001]
  • [Cites] Oncogene. 1991 Apr;6(4):543-51 [1827666.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] J Biol Chem. 1991 Sep 15;266(26):17531-6 [1894635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11445-9 [1763059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7070-4 [1386673.001]
  • (PMID = 18375384.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Activating Transcription Factor 1; 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / DNA-Binding Proteins; 0 / Gene Products, tax; 0 / Repressor Proteins; 0 / ZNF268 protein, human; E0399OZS9N / Cyclic AMP
  • [Other-IDs] NLM/ PMC2423250
  •  go-up   go-down


10. Yasunaga J, Matsuoka M: Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control; 2007 Apr;14(2):133-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms.
  • BACKGROUND: Human T-cell leukemia virus type I (HTLV-I) is a causative virus of adult T-cell leukemia (ATL), HTLV-I-associated myelopathy/tropical spastic paraparesis, and HTLV-I-associated uveitis.
  • Effectiveness of allogeneic stem cell transplantation for ATL has been recently reported.
  • [MeSH-major] CD4-Positive T-Lymphocytes / virology. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Gene Expression Regulation, Viral. Genes, pX. Humans. NF-kappa B / antagonists & inhibitors. Viral Proteins / genetics

  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387298.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antibodies, Monoclonal; 0 / NF-kappa B; 0 / Viral Proteins
  • [Number-of-references] 79
  •  go-up   go-down


11. Jeang KT: Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget; 2010 Oct;1(6):453-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?
  • The mechanism of HTLV-1 transformation of cells to Adult T cell leukemia (ATL) remains not fully understood.
  • [MeSH-minor] Adult. HTLV-I Infections / genetics. HTLV-I Infections / virology. Humans

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Nat Med. 2007 May;13(5):527-8 [17479090.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):531-8 [17661351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] Retrovirology. 2007;4:82 [18036240.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8976-85 [18974142.001]
  • [Cites] Retrovirology. 2008;5:100 [19014482.001]
  • [Cites] Blood. 2009 May 14;113(20):4914-7 [19246560.001]
  • [Cites] Virus Res. 2009 Aug;143(2):195-208 [19540281.001]
  • [Cites] Nat Rev Genet. 2009 Oct;10(10):704-14 [19763153.001]
  • [Cites] Genes Dev. 2009 Dec 1;23(23):2700-4 [19903759.001]
  • [Cites] Retrovirology. 2009;6:117 [20017952.001]
  • [Cites] Retrovirology. 2010;7:17 [20222966.001]
  • [Cites] J Biol Chem. 2010 Aug 6;285(32):24707-16 [20529860.001]
  • [Cites] Mol Aspects Med. 2010 Oct;31(5):367-82 [20600265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6698-703 [9506967.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • (PMID = 21311101.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AI001023-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS242806; NLM/ PMC3058865
  •  go-up   go-down


12. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF, Liang R: Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis; 2010 Apr;31(4):745-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the role of miR-34a methylation in a panel of hematological malignancies including acute leukemia [acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)], chronic leukemia [chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)], multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).
  • The methylation status of miR-34a promoter was studied in 12 cell lines and 188 diagnostic samples by methylation-specific polymerase chain reaction. miR-34a promoter was unmethylated in normal controls but methylated in 75% lymphoma and 37% myeloma cell lines.
  • Amongst lymphoid malignancies, miR-34a was preferentially methylated in NHL (P = 0.018), in particular natural killer (NK)/T-cell lymphoma.
  • In conclusion, amongst hematological malignancies, miR-34a methylation is preferentially hypermethylated in NHL, in particular NK/T-cell lymphoma, in a tumor-specific manner, therefore the role of miR-34a in lymphomagenesis warrants further study.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Genes, p53. Humans. Loss of Heterozygosity. Male. Middle Aged. Polymerase Chain Reaction. Promoter Regions, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Carcinogenesis. 2014 Nov;35(11):2631
  • (PMID = 20118199.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN34 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


13. Taylor JM, Brown M, Nejmeddine M, Kim KJ, Ratner L, Lairmore M, Nicot C: Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission. J Virol; 2009 Nov;83(22):11467-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia/lymphoma, and it encodes a number of nonstructural proteins that are involved in virus replication and immune evasion.
  • Using a previously established T-cell line immortalized with an HTLV-1 molecular clone deleted for p12, we assessed the role of p12 in regulating cellular growth and virus transmission.
  • Consistently with previous studies, p12- and p12+ cell lines produced similar amounts of virus particles released into the supernatant of cultured cells, although we found that p12 expression greatly enhanced virus transmission.
  • Intriguingly, IL-2/Jak signaling was not associated with changes in viral gene expression, viral RNA encapsidation, the maturation of the virus particle, cell-cell adherence, or Gag polarization and virological synapse formation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2007 Sep;81(17):9088-99 [17582004.001]
  • [Cites] J Virol. 2007 Sep;81(18):9707-17 [17609265.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):98-108 [18182620.001]
  • [Cites] Nat Med. 2008 Apr;14(4):429-36 [18376405.001]
  • [Cites] J Virol. 2008 Jul;82(14):7135-43 [18480461.001]
  • [Cites] Retrovirology. 2008;5:105 [19032754.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1016-25 [19494354.001]
  • [Cites] Nature. 1988 Oct 20;335(6192):738-40 [3262832.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7329-33 [1976256.001]
  • [Cites] J Virol. 1992 Feb;66(2):906-13 [1530980.001]
  • [Cites] J Virol. 1992 Mar;66(3):1737-45 [1310774.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3005-9 [1348363.001]
  • [Cites] J Virol. 1992 Jul;66(7):4601-5 [1602562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8813-7 [1528897.001]
  • [Cites] J Immunol. 1992 Nov 1;149(9):2879-86 [1401919.001]
  • [Cites] J Virol. 1993 Mar;67(3):1590-9 [8382312.001]
  • [Cites] J Virol. 1993 Dec;67(12):7701-4 [8230493.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):554-61 [7530239.001]
  • [Cites] J Virol Methods. 1995 Jan;51(1):19-29 [7730434.001]
  • [Cites] Science. 1995 Jul 7;269(5220):79-81 [7604283.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1548-55 [7657825.001]
  • [Cites] Oncogene. 1995 Sep 7;11(5):993-8 [7675460.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3619-39 [7579327.001]
  • [Cites] J Cell Sci. 2000 Jan;113 ( Pt 1):37-44 [10591623.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Virology. 2000 Aug 15;274(1):86-93 [10936091.001]
  • [Cites] J Virol. 2000 Nov;74(21):9828-35 [11024109.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1777-81 [11080826.001]
  • [Cites] J Virol. 2001 Aug;75(16):7351-61 [11462007.001]
  • [Cites] Blood. 2001 Aug 1;98(3):823-9 [11468184.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1200-8 [11493471.001]
  • [Cites] J Virol. 2002 Apr;76(7):3493-501 [11884573.001]
  • [Cites] J Virol. 2002 May;76(10):4709-22 [11967288.001]
  • [Cites] J Virol. 2002 Aug;76(16):8485-93 [12134053.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1713-6 [12589003.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):226-37, table of contents [12794191.001]
  • [Cites] J Virol. 2003 Oct;77(20):11027-39 [14512551.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] J Cell Sci. 2004 Aug 1;117(Pt 17):3983-93 [15286176.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2852-9 [15353320.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2523-31 [15226182.001]
  • [Cites] J Exp Med. 1973 Feb 1;137(2):387-410 [4568301.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):268-71 [6272125.001]
  • [Cites] Int J Cancer. 1983 Sep 15;32(3):321-8 [6604033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Dec;80(23):7337-41 [6316359.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • [Cites] Cell. 1987 Apr 10;49(1):47-56 [3030566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] Science. 1996 Apr 12;272(5259):263-7 [8602510.001]
  • [Cites] J Virol. 1997 Jan;71(1):259-66 [8985345.001]
  • [Cites] J Virol. 1997 Feb;71(2):1173-80 [8995639.001]
  • [Cites] J Virol. 1997 Jun;71(6):4445-51 [9151835.001]
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3845-50 [9520455.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4701-7 [9616168.001]
  • [Cites] J Gen Virol. 1999 Jun;80 ( Pt 6):1429-36 [10374960.001]
  • [Cites] J Virol. 1999 Nov;73(11):9642-9 [10516077.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jan;21(1):43-50 [15665643.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):419-30 [15699074.001]
  • [Cites] Blood. 2005 Aug 1;106(3):988-95 [15831709.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1169-74 [15902300.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29653-60 [15975923.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] J Immunol. 2006 May 1;176(9):5463-70 [16622014.001]
  • [Cites] J Virol. 2006 May;80(10):4771-80 [16641270.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • (PMID = 19726513.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115398; United States / NCI NIH HHS / CA / P01 CA100730-07; United States / NCI NIH HHS / CA / CA100730; United States / NCI NIH HHS / CA / CA63417; United States / NCI NIH HHS / CA / CA10521; United States / NCI NIH HHS / CA / CA106258; United States / NCI NIH HHS / CA / CA70529; United States / NCI NIH HHS / CA / R01 CA063417; United States / NCI NIH HHS / CA / CA100730-07; United States / NCI NIH HHS / CA / P01 CA100730; United States / NCI NIH HHS / CA / CA115398; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Retroviridae Proteins, Oncogenic; 0 / STAT Transcription Factors; 0 / Viral Regulatory and Accessory Proteins; 0 / p12I protein, Human T-lymphotropic virus 1; EC 2.7.10.2 / Janus Kinases
  • [Other-IDs] NLM/ PMC2772716
  •  go-up   go-down


14. Retraction. Tanji H, Ishikawa C, Sawada S, Nakachi S, Takamatsu R, Matsuda T, Okudaira T, Uchihara J-N, Ohshiro K, Tanaka Y, Senba M, Uezato H, Ohshima K, Duc Dodon M, Wu K-J, Mori N. Aberrant expression of the transcription factor Twist in adult T-cell leukemia [published online ahead of print January 13, 2010]. Blood. doi:10.1182/blood-2009-07-232231. Blood; 2010 Aug 26;116(8):1386
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retraction. Tanji H, Ishikawa C, Sawada S, Nakachi S, Takamatsu R, Matsuda T, Okudaira T, Uchihara J-N, Ohshiro K, Tanaka Y, Senba M, Uezato H, Ohshima K, Duc Dodon M, Wu K-J, Mori N. Aberrant expression of the transcription factor Twist in adult T-cell leukemia [published online ahead of print January 13, 2010]. Blood. doi:10.1182/blood-2009-07-232231.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionOf] Tanji H, Ishikawa C, Sawada S, Nakachi S, Takamatsu R, Matsuda T, Okudaira T, Uchihara JN, Ohshiro K, Tanaka Y, Senba M, Uezato H, Ohshima K, Duc Dodon M, Wu KJ, Mori N. Blood. 2010 Jan 13;. doi: 10.1182/blood-2009-07-232231 [20071663.001]
  • (PMID = 20574045.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Retraction of Publication
  • [Publication-country] United States
  •  go-up   go-down


15. Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K, Ido A, Matsuoka H, Okayama A, Nakanishi T, Tsubouchi H: Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma; 2005 Mar;46(3):393-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia.
  • The study was carried out in 22 patients with adult T-cell leukemia (ATL) (7 chronic and 15 acute types) and in 13 asymptomatic human T-lymphotropic virus type 1 (HTLV-1) carriers.
  • The mean values of TA in acute and chronic type patients were 13.8 and 1.6 total product generated (TPG) units, respectively, as determined by telomeric repeat amplification assays.
  • The mean TA value in acute type patients was significantly higher than in the three other subject groups.
  • The mean TL values in patients with acute and chronic types were 5.39 and 4.38 Kb, respectively, while the mean TL values in HTLV-1 carriers and healthy volunteers were 7.69 and 7.06 Kb, respectively.
  • Neither TA nor TL of ATL cells showed any significant association with the number of ATL cells, serum soluble interleukin-2 receptor, or serum lactate dehydrogenase in the peripheral blood of acute type patients.
  • The median survival period of acute ATL patients with high TA and shortened TL was 0.47 years, however, which was significantly shorter than that of acute ATL patients with low TA and normal TL (4.21 years) (p < 0.002).
  • [MeSH-major] HTLV-I Infections / enzymology. Leukemia-Lymphoma, Adult T-Cell / enzymology. Telomerase / metabolism. Telomere / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / enzymology. Male. Middle Aged. Prognosis. Prospective Studies. Restriction Mapping. Serologic Tests. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


16. Nicot C: Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol; 2005 Mar;78(3):232-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current views in HTLV-I-associated adult T-cell leukemia/lymphoma.
  • HTLV-I is the etiological agent of adult T-cell leukemia/lymphoma (ATLL) and is also associated with cutaneous T-cell lymphoma (CTCL).
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726602.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI058944; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


17. Ravandi F, Faderl S: Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res; 2006 Jan;30(1):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
  • Treatment of adult T-cell leukemia (ATL) remains difficult.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979704.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab
  •  go-up   go-down


18. Ishizawa J, Fujita H, Iguchi M, Tachibana T, Taguchi J, Ishigatsubo Y: Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovir. Int J Hematol; 2007 Apr;85(3):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV).
  • [MeSH-minor] Adult. Cord Blood Stem Cell Transplantation / adverse effects. DNA, Viral / blood. DNA, Viral / drug effects. Female. Humans. Injections, Intravenous. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Shingles.
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect. 2003 Aug;47(2):133-8 [12860147.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):1003-5 [10800071.001]
  • [Cites] Lancet. 2001 Jun 30;357(9274):2101-2 [11445106.001]
  • [Cites] J Infect Dis. 1985 Dec;152(6):1172-81 [3905982.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2568-73 [10878045.001]
  • [Cites] Bone Marrow Transplant. 1995 May;15(5):805-7 [7670413.001]
  • [Cites] Intern Med. 2004 Sep;43(9):861-4 [15497526.001]
  • (PMID = 17483062.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; X4HES1O11F / Acyclovir
  •  go-up   go-down


19. Pirot N, Deleuze V, El-Hajj R, Dohet C, Sablitzky F, Couttet P, Mathieu D, Pinet V: LYL1 activity is required for the maturation of newly formed blood vessels in adulthood. Blood; 2010 Jun 24;115(25):5270-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we reveal a role for Lyl1 as a major regulator of adult neovascularization.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418284.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Antigens, CD; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cadherins; 0 / LYL1 protein, human; 0 / Lyl1 protein, mouse; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; 0 / Tal1 protein, mouse; 0 / cadherin 5
  •  go-up   go-down


20. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M, Japan Clinical Oncology Group Study JCOG9801: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol; 2007 Dec 1;25(34):5458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
  • PURPOSE: Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL) with vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP), doxorubicin, ranimustine, and prednisone (AMP), and vindesine, etoposide, carboplatin, and prednisone (VECP) showed promising results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Prednisone / administration & dosage. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968021.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; RYH2T97J77 / ranimustine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Tomita M, Tanaka Y, Mori N: Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. Int J Cancer; 2010 Oct 1;127(7):1584-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aurora kinases play an essential role in regulating mitosis and cell division.
  • Inhibition of Aurora kinases results in suppression of cell division, phosphorylation of histone H3 and induction of apoptosis in many cell types.
  • In our study, we report the in vitro activities of AZD1152, a selective inhibitor of Aurora B kinase in human T-cell leukemia virus type 1 (HTLV-1), the causative agent of adult T-cell leukemia (ATL), -infected T-cell lines.
  • Overexpression of Aurora B was noted in HTLV-1-infected T-cell lines compared to HTLV-1-uninfected T-cell lines.
  • AZD1152 reduced the viability of HTLV-1-infected T-cell lines within 24 hr but did not affect that of -uninfected T-cell lines.
  • Although AZD1152 inhibited phosphorylation of histone H3 on Ser10 in both HTLV-1-infected and -uninfected T-cell lines, it induced polyploidy only in HTLV-1-uninfected T-cell lines.
  • We have reported previously that a pan-Aurora kinase inhibitor induced apoptosis through inhibition of NF-kappaB signaling activity in HTLV-1-infected T-cell lines.
  • It induced p53 and p21 expression in HTLV-1-infected but not in HTLV-1-uninfected T-cell lines, suggesting that activation of p53-dependent postmitotic checkpoint might prevent polyploidy in HTLV-1-infected T-cells.
  • [MeSH-major] Cell Survival / drug effects. Human T-lymphotropic virus 1 / pathogenicity. Organophosphates / pharmacology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Quinazolines / pharmacology. T-Lymphocytes / virology
  • [MeSH-minor] Aurora Kinase B. Aurora Kinases. B-Lymphocytes / cytology. B-Lymphocytes / drug effects. Cell Cycle / drug effects. Cell Division / drug effects. Enzyme Inhibitors / pharmacology. Humans. Jurkat Cells / drug effects. Jurkat Cells / pathology. NF-kappa B / drug effects. NF-kappa B / physiology. RNA, Small Interfering / genetics. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Int J Cancer. 2011 Dec 1;129(11):2762-3 [21960263.001]
  • (PMID = 20091867.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; 0 / Enzyme Inhibitors; 0 / NF-kappa B; 0 / Organophosphates; 0 / Quinazolines; 0 / RNA, Small Interfering; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


22. Yasunami T, Wang YH, Tsuji K, Takanashi M, Yamada Y, Motoji T: Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res; 2007 Apr;31(4):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.
  • In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins.
  • [MeSH-major] Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134750.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 80168379AG / Doxorubicin
  •  go-up   go-down


23. Yamasaki M, Fujita S, Ishiyama E, Mukai A, Madhyastha H, Sakakibara Y, Suiko M, Hatakeyama K, Nemoto T, Morishita K, Kataoka H, Tsubouchi H, Nishiyama K: Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo. Cancer Sci; 2007 Nov;98(11):1740-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo.
  • Adult T-cell leukemia occurs in human T-lymphotropic virus type I-infected individuals and is endemic to the south-western area of Kyushu in Japan.
  • In this communication, we examined the effect of soy isoflavones on the growth of adult T-cell leukemia cells in vitro and in vivo.
  • Among the isoflavones studied, genistein had the highest growth-inhibitory effect; however, genistein did not exert an apparent growth-inhibitory effect on Jurkat and Molt-4 cells, which were non-adult T-cell leukemia cells.
  • The in vivo studies demonstrated that soy-derived isoflavones significantly inhibit ED-40515 cell growth and infiltration into various organs in non-obese diabetic severe combined-immunodeficiency common gamma-chain knockout mice.
  • Taken together, it is evident that soy isoflavones might serve as a promising compound for the treatment of adult T-cell leukemia.
  • [MeSH-major] Isoflavones / pharmacology. Isoflavones / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Soybeans
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Genistein / pharmacology. Humans. Jurkat Cells. Mice. Mice, Knockout. Mice, SCID. Transplantation, Heterologous

  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727682.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoflavones; 6287WC5J2L / daidzein; 92M5F28TVF / glycitein; DH2M523P0H / Genistein
  •  go-up   go-down


24. Kang SK, Lee MY, Kim TK, Lee JO, Ahn YS: Occupational exposure to benzene in South Korea. Chem Biol Interact; 2005 May 30;153-154:65-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-four cases of hematopoietic diseases were investigated by KOSHA including eight cases of myelodysplastic syndrome and eight cases of acute myelocytic leukemia.
  • [MeSH-minor] Adult. Biomarkers / urine. Environmental Monitoring. Epidemiological Monitoring. Female. Hematologic Tests. Humans. Industry / classification. Korea / epidemiology. Leukemia, Lymphocytic, Chronic, B-Cell / chemically induced. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / epidemiology. Male. Middle Aged. Multiple Myeloma / chemically induced. Multiple Myeloma / epidemiology. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / epidemiology. Occupational Diseases / chemically induced. Occupational Diseases / epidemiology. Phenol / urine. Sorbic Acid / analogs & derivatives. Sorbic Acid / analysis

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. PHENOL .
  • Hazardous Substances Data Bank. SORBIC ACID .
  • Hazardous Substances Data Bank. SODIUM PHENOLATE .
  • Hazardous Substances Data Bank. BENZENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15935801.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Biomarkers; 339NCG44TV / Phenol; 3KD92ZL2KH / muconic acid; J64922108F / Benzene; X045WJ989B / Sorbic Acid
  •  go-up   go-down


25. Yamada T, Mishima K, Ota A, Moritani N, Matsumura T, Katase N, Yamamoto T: A case of ATLL (adult T-cell leukemia/lymphoma) mimicking odontogenic infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun;109(6):e51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ATLL (adult T-cell leukemia/lymphoma) mimicking odontogenic infection.
  • A case of adult T-cell leukemia/lymphoma (ATLL) in which cheek swelling was the initial symptom is presented.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Maxilla / pathology. Periapical Abscess / pathology. Soft Tissue Infections / pathology. Tooth Diseases / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Tooth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20451832.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Nadella MV, Dirksen WP, Nadella KS, Shu S, Cheng AS, Morgenstern JA, Richard V, Fernandez SA, Huang TH, Guttridge D, Rosol TJ: Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia; 2007 Aug;21(8):1752-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma.
  • Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy (HHM) that occurs in the majority of patients with adult T-cell leukemia/lymphoma (ATLL) due to human T-cell lymphotropic virus type-1 (HTLV-1) infection.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Sep;71(9):6277-8 [9261343.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33132-9 [9407099.001]
  • [Cites] Immunol Today. 1998 Feb;19(2):80-8 [9509763.001]
  • [Cites] Annu Rev Physiol. 1998;60:431-60 [9558472.001]
  • [Cites] J Bone Miner Res. 1999 Mar;14(3):406-14 [10027905.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Virology. 1996 Dec 15;226(2):167-75 [8955035.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1035-45 [8704212.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1342-8 [8657107.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1349-57 [8625910.001]
  • [Cites] Eur J Haematol. 1996 Jan-Feb;56(1-2):116-7 [8599987.001]
  • [Cites] Miner Electrolyte Metab. 1995;21(1-3):166-70 [7565442.001]
  • [Cites] J Biol Chem. 1995 Feb 17;270(7):3123-31 [7852394.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] Genes Dev. 1993 Jul;7(7B):1354-63 [8330739.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5785-99 [10409765.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1175-83 [15889157.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Mol Cell. 2006 Feb 3;21(3):393-404 [16455494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5899-904 [16595631.001]
  • [Cites] Immunol Res. 2006;34(1):1-12 [16720895.001]
  • [Cites] J Virol. 1993 Jul;67(7):4205-13 [8510222.001]
  • [Cites] Mol Endocrinol. 1993 Feb;7(2):273-82 [8469240.001]
  • [Cites] Cell. 1993 Mar 12;72(5):729-39 [8453667.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:421-4 [1490380.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Dec 15;189(2):938-43 [1472066.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1642-52 [1280327.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):339-42 [1406939.001]
  • [Cites] Mol Endocrinol. 1990 Jun;4(6):851-8 [2233743.001]
  • [Cites] Gene. 1989 Apr 15;77(1):95-105 [2744490.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):556-63 [3043221.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Genes Dev. 2004 Sep 15;18(18):2195-224 [15371334.001]
  • [Cites] Cell. 2004 Aug 20;118(4):453-64 [15315758.001]
  • [Cites] Neoplasia. 2004 May-Jun;6(3):266-78 [15153339.001]
  • [Cites] EMBO J. 1997 Jun 16;16(12):3609-20 [9218802.001]
  • [Cites] J Neurochem. 2000 Oct;75(4):1377-89 [10987817.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6977-84 [11156399.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45380-6 [11567031.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9722-32 [12509424.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2789-96 [12456498.001]
  • (PMID = 17554373.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCRR NIH HHS / RR / RR07073; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / T32 RR007073; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; None / None / / P01 CA100730-01; United States / NCI NIH HHS / CA / P01 CA100730-01; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; EC 2.3.1.28 / Chloramphenicol O-Acetyltransferase
  • [Other-IDs] NLM/ NIHMS94363; NLM/ PMC2676796
  •  go-up   go-down


27. Adams H, Schmid P, Dirnhofer S, Tzankov A: Cytokeratin expression in hematological neoplasms: a tissue microarray study on 866 lymphoma and leukemia cases. Pathol Res Pract; 2008;204(8):569-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin expression in hematological neoplasms: a tissue microarray study on 866 lymphoma and leukemia cases.
  • Using tissue microarray technology, we tested 1059 lymphoma and acute leukemia cases, covering the most common disease entities, for aberrant CK expression, using CK22.
  • In total, 866 of the arrayed cases were evaluable (80%), and 13 positive cases (1.5%) were found: 1 out of 230 Hodgkin lymphomas (0.4%), 1 plasma cell myeloma, 2 out of 326 diffuse large B-cell lymphomas (0.6%), 5 out of 18 mantle cell lymphomas (26%), 3 out of 70 small cell lymphomas/chronic lymphocytic leukemias (4%) and 1 out of 27 peripheral T-cell lymphomas, not otherwise specified (4%).
  • All CK22-positive cases, except for one mantle cell lymphoma, expressed the specific simple epithelial CK8 but not the basal/stratified epithelial CK5/6.
  • Aberrant CK expression can be encountered in a small subset of otherwise characteristic B- and T-cell lymphomas, but not in acute leukemias, which should be considered in difficult differential diagnostic settings.
  • [MeSH-major] Keratins / analysis. Leukemia / metabolism. Lymphoma / chemistry. Tissue Array Analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Europe. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436389.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


28. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD: Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica; 2010 Jun;95(6):942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival.
  • Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse.
  • No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.
  • The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy.
  • In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.
  • T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.
  • In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.
  • CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients.
  • Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Exp Hematol. 1997 Apr;25(4):312-20 [9131006.001]
  • [Cites] Leukemia. 1997 May;11(5):639-43 [9180285.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3990-4003 [10406804.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Haematologica. 2006 Feb;91(2):270-1 [16461320.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Oncogene. 2006 Jul 13;25(30):4217-29 [16518414.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Expert Rev Mol Med. 2007;9(14):1-17 [17524167.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3303-12 [16380455.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1914-22 [11753613.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):409-20 [11841446.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):463-70 [12841384.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):6198-206 [8119964.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • (PMID = 20435628.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2878792
  •  go-up   go-down


29. Nakazato T, Okudaira T, Ishikawa C, Nakama S, Sawada S, Tomita M, Uchihara JN, Taira N, Masuda M, Tanaka Y, Ohshiro K, Takasu N, Mori N: Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene). Cancer Sci; 2008 Nov;99(11):2286-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (Tamibarotene).
  • Clinical trials for treatment of adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type I (HTLV-I) using all-trans-retinoic acid (ATRA) have shown satisfactory therapeutic responses, although efficacies were limited.
  • The present study examined the inhibitory effects of Am80 on HTLV-I-infected T-cell lines and ATL cells.
  • Am80 had negligible growth inhibition of peripheral blood mononuclear cells but marked growth inhibition of both HTLV-I-infected T-cell lines and ATL cells.
  • Am80 arrested cells in the G1 phase of the cell cycle and induced apoptosis in HTLV-I-infected T-cell lines.
  • It inhibited also the phosphorylation of IkappaBalpha and NF-kappaB-DNA binding, in conjunction with reduction of expression of proteins involved in the G1/S cell cycle transition and apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzoates / pharmacology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tetrahydronaphthalenes / pharmacology
  • [MeSH-minor] Animals. Cell Cycle. Cell Division. Cell Line, Tumor. Female. Human T-lymphotropic virus 1 / pathogenicity. Humans. Mice. Mice, SCID

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Nakamura Y. Cancer Sci. 2011 Feb;102(2):499 [21265954.001]
  • (PMID = 18771528.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Tetrahydronaphthalenes; 08V52GZ3H9 / tamibarotene
  •  go-up   go-down


30. Nakamura M, Hamasaki T, Tokitou M, Baba M, Hashimoto Y, Aoyama H: Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis. Bioorg Med Chem; 2009 Jul 1;17(13):4740-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of tetrahydrotetramethylnaphthalene analogs as adult T-cell leukemia cell-selective proliferation inhibitors in a small chemical library constructed based on multi-template hypothesis.
  • Adult T cell leukemia (ATL), caused by infection of human T-lymphotropic virus type 1 (HTLV-1), has a poor prognosis and curative therapy is unavailable, so it is important to find or design superior lead compounds for the drug treatment of ATL.
  • We used our micro-reversed fragment-based drug design hypothesis and multi-template hypothesis to extract the tetrahydrotetramethylnaphthalene (TMN) skeleton from tamibarotene, a useful medicament for the treatment of acute promyelocytic leukemia (APL).
  • Structural development of TMN yielded highly ATL cell-selective growth inhibitors, including 2-acetyl-3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene (6).
  • Structure-activity relationship analysis suggests the existence of a specific target molecule for ATL cell-selective inhibition of proliferation through G2 arrest.
  • [MeSH-major] Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tetrahydronaphthalenes / chemistry. Tetrahydronaphthalenes / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Drug Design. Human T-lymphotropic virus 1 / isolation & purification. Humans. Models, Molecular. Molecular Structure. Retinoids. Small Molecule Libraries. Structure-Activity Relationship. T-Lymphocytes / cytology. T-Lymphocytes / virology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443225.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Retinoids; 0 / Small Molecule Libraries; 0 / Tetrahydronaphthalenes
  •  go-up   go-down


31. Kesic M, Doueiri R, Ward M, Semmes OJ, Green PL: Phosphorylation regulates human T-cell leukemia virus type 1 Rex function. Retrovirology; 2009 Nov 17;6:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation regulates human T-cell leukemia virus type 1 Rex function.
  • BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1) is a pathogenic complex deltaretrovirus, which is the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1990 Jun 15;169(2):469-75 [2357216.001]
  • [Cites] Nature. 1989 Oct 5;341(6241):453-6 [2677743.001]
  • [Cites] J Virol. 1991 Jan;65(1):546-50 [1898667.001]
  • [Cites] J Virol. 1991 Jan;65(1):81-8 [1985219.001]
  • [Cites] Neurology. 1991 Jan;41(1):85-7 [1985300.001]
  • [Cites] J Virol. 1991 Jun;65(6):3379-83 [2033676.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5704-8 [1905815.001]
  • [Cites] J Virol. 1991 Aug;65(8):4408-13 [2072457.001]
  • [Cites] J Virol. 1991 Nov;65(11):6001-7 [1920623.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):645-6 [1347339.001]
  • [Cites] J Virol. 1992 Apr;66(4):2583-7 [1548784.001]
  • [Cites] J Virol. 1992 Jul;66(7):4325-30 [1602546.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21977-81 [1400509.001]
  • [Cites] Virology. 1993 Mar;193(1):41-9 [8438577.001]
  • [Cites] Protein Sci. 1993 Mar;2(3):348-56 [8453373.001]
  • [Cites] J Virol. 1993 May;67(5):2496-502 [8474155.001]
  • [Cites] Ann Neurol. 1993 Apr;33(4):411-4 [8489213.001]
  • [Cites] J Virol. 1996 Sep;70(9):6442-5 [8709278.001]
  • [Cites] J Virol. 1996 Aug;70(8):5194-202 [8764028.001]
  • [Cites] J Virol. 1997 Feb;71(2):1181-90 [8995640.001]
  • [Cites] Blood Rev. 1997 Jun;11(2):91-104 [9242992.001]
  • [Cites] J Virol. 1997 Nov;71(11):8912-7 [9343258.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] J Virol. 1998 Aug;72(8):6602-7 [9658105.001]
  • [Cites] J Virol. 1998 Nov;72(11):8852-60 [9765430.001]
  • [Cites] Anal Chem. 1999 Jan 1;71(1):235-42 [9921130.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] J Virol. 1999 Oct;73(10):8112-9 [10482560.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:620-42 [15569604.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:431-45 [15574380.001]
  • [Cites] Bioessays. 2005 Mar;27(3):285-98 [15714552.001]
  • [Cites] Mol Cell Proteomics. 2005 Mar;4(3):235-45 [15640519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31705-12 [16923801.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):25088-99 [17597071.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Nov;8(11):904-16 [17878917.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] Retrovirology. 2008;5:92 [18922151.001]
  • [Cites] Retrovirology. 2009;6:9 [19187529.001]
  • [Cites] J Virol. 2009 May;83(10):5232-43 [19279097.001]
  • [Cites] J Virol. 2009 Sep;83(17):8859-68 [19553333.001]
  • [Cites] J Virol. 2000 Mar;74(6):2655-62 [10684280.001]
  • [Cites] N Engl J Med. 2000 Mar 30;342(13):930-6 [10738051.001]
  • [Cites] J Virol. 2001 Sep;75(18):8440-8 [11507189.001]
  • [Cites] Curr Opin Chem Biol. 2001 Oct;5(5):591-602 [11578935.001]
  • [Cites] J Virol. 2003 Jul;77(14):7728-35 [12829812.001]
  • [Cites] J Biomol Tech. 2003 Sep;14(3):205-15 [13678151.001]
  • [Cites] Prog Cell Cycle Res. 2003;5:477-87 [14593743.001]
  • [Cites] J Virol. 2003 Dec;77(23):12829-40 [14610204.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3963-9 [12907436.001]
  • [Cites] Science. 1985 Aug 16;229(4714):675-9 [2992082.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):571-4 [2999613.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Blood. 1988 Feb;71(2):363-9 [2827811.001]
  • [Cites] Cell. 1988 Oct 21;55(2):197-209 [3048703.001]
  • [Cites] Cell. 1989 Jul 14;58(1):205-14 [2752419.001]
  • [Cites] Virology. 1990 Sep;178(1):327-30 [2202148.001]
  • (PMID = 19919707.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076595; United States / NCI NIH HHS / CA / CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, rex; 0 / rex Protein, Human T-lymphotropic virus 1; 1114-81-4 / Phosphothreonine; 17885-08-4 / Phosphoserine
  • [Other-IDs] NLM/ PMC2780990
  •  go-up   go-down


32. Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, Weisenburger DD, International Peripheral T-Cell Lymphoma Project: The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol; 2009 Apr;20(4):715-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project.
  • BACKGROUND: The International Peripheral T-cell Lymphoma Project was organized to better understand the T-cell and natural killer (NK) cell lymphomas, and our task is to present the clinicopathologic correlations and therapeutic results for adult T-cell leukemia/lymphoma (ATL).
  • PATIENTS AND METHODS: Among 1153 patients with T-cell or NK cell lymphomas, 126 patients (9.6%) with ATL were represented in this project.
  • All were categorized as aggressive ATL, i.e. acute or lymphoma type, and 87% fell into the lymphoma type.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150954.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Savage K; Connors J; Gascoyne R; Chhanabhai M; Wilson W; Jaffe E; Armitage J; Vose J; Weisenburger D; Anderson J; Ullrich F; Bast M; Hochberg E; Harris N; Levine A; Nathwani B; Miller T; Rimsza L; Montserrat E; Lopez-Guillermo A; Campo E; Cuadros M; Alvarez Ferreira J; Martinez Delgado B; Holte H; Delabie J; Rüdiger T; Müller-Hermelink K; Reimer P; Adam P; Wilhelm M; Schmitz N; Nerl C; MacLennan KA; Zinzani PL; Pileri S; Federico M; Bellei M; Coiffier B; Berger F; Tanin I; Wannakrairot P; Au W; Liang R; Loong F; Rajan S; Sng I; Tobinai K; Matsuno Y; Morishima Y; Nakamura S; Seto M; Tanimoto M; Yoshino T; Suzumiya J; Ohshima K; Kim WS; Ko YH
  •  go-up   go-down


33. Haider S, Hayakawa K, Itoyama T, Sadamori N, Kurosawa N, Isobe M: TCR variable gene involvement in chromosome inversion between 14q11 and 14q24 in adult T-cell leukemia. J Hum Genet; 2006;51(4):326-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCR variable gene involvement in chromosome inversion between 14q11 and 14q24 in adult T-cell leukemia.
  • Chromosomal translocations in T-cell malignancies frequently involve the T-cell receptor (TCR)alpha/delta locus at chromosome 14q11.
  • Although 14q11 abnormalities are found in about 10% of adult T-cell leukemia (ATL) cases, until now there has been no direct evidence showing involvement of the TCR locus in ATL-a malignancy closely associated with HTLV-1 infection.
  • The breakpoints of T-cell malignancies most commonly occur within the Jalpha or Jdelta region of the TCR locus.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 14. Gene Expression Regulation, Leukemic. Genes, T-Cell Receptor. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] ADAM Proteins / metabolism. Adult. Animals. Base Sequence. Blotting, Southern. COS Cells. Cells, Cultured. Cercopithecus aethiops. DNA / genetics. Electrophoresis, Polyacrylamide Gel. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Leukocytes, Mononuclear / cytology. Membrane Proteins / metabolism. Models, Genetic. Molecular Sequence Data. Restriction Mapping. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Transfection

  • Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520872.001).
  • [ISSN] 1434-5161
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ202398/ DQ302756
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Membrane Proteins; 9007-49-2 / DNA; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins
  •  go-up   go-down


34. Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, Oldani E, Grassi A, Intermesoli T, Micò C, Rossi G, Fabris P, Lambertenghi-Deliliers G, Angelucci E, Barbui T, Bassan R, Rambaldi A: Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica; 2007 May;92(5):612-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
  • BACKGROUND AND OBJECTIVES: The molecular analysis of minimal residual disease (MRD) may provide information on the risk of recurrence in patients with acute lymphoblastic leukemia (ALL).
  • DESIGN AND METHODS: MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) using probes derived from fusion chimeric genes (BCR/ABL and MLL/AF4) (n=22) or rearrangements of the T-cell receptor or immunoglobulin genes (n=21).
  • Forty-three adult patients with ALL were studied to correlate the kinetics of MRD clearance before and after allogeneic hematopoietic stem cell transplantation.
  • INTERPRETATION AND CONCLUSIONS: The kinetics of MRD clearance may help to identify patients at high risk of leukemia relapse after allogeneic stem cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Transplantation, Homologous
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Basic Helix-Loop-Helix Transcription Factors / genetics. Benzamides. Biomarkers, Tumor / blood. Clinical Trials as Topic / statistics & numerical data. Cohort Studies. Combined Modality Therapy. Female. Fusion Proteins, bcr-abl / blood. Gene Deletion. Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, T-Lymphocyte. Humans. Imatinib Mesylate. Kaplan-Meier Estimate. Kinetics. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / surgery. Male. Middle Aged. Multicenter Studies as Topic. Myeloid-Lymphoid Leukemia Protein / blood. Neoplasm, Residual. Oncogene Proteins, Fusion / blood. Piperazines / administration & dosage. Polymerase Chain Reaction. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / surgery. Proto-Oncogene Proteins / genetics. Pyrimidines / administration & dosage. Remission Induction. Risk. Survival Analysis. Survival Rate. Translocation, Genetic. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488684.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Proto-Oncogene Proteins; 0 / Pyrimidines; 135471-20-4 / TAL1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


35. Okajima M, Takahashi M, Higuchi M, Ohsawa T, Yoshida S, Yoshida Y, Oie M, Tanaka Y, Gejyo F, Fujii M: Human T-cell leukemia virus type 1 Tax induces an aberrant clustering of the tumor suppressor Scribble through the PDZ domain-binding motif dependent and independent interaction. Virus Genes; 2008 Oct;37(2):231-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type 1 Tax induces an aberrant clustering of the tumor suppressor Scribble through the PDZ domain-binding motif dependent and independent interaction.
  • Human T-cell leukemia virus type 1 (HTLV-1) is a causative agent of adult T-cell leukemia.
  • Endogenous Scribble was diffusely localized at the plasma membrane of HTLV-1-uninfected T-cell lines, whereas it colocalized with Tax1 as small and large aggregate at the plasma membranes.
  • [MeSH-minor] Binding Sites. Cell Line. Cell Membrane / genetics. Cell Membrane / metabolism. Humans. Jurkat Cells. PDZ Domains. Protein Binding. Protein Transport

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2003 Feb 1;306(1):60-7 [12620798.001]
  • [Cites] Int Rev Cytol. 2007;262:253-302 [17631191.001]
  • [Cites] Int J Cancer. 1991 Jun 19;48(4):623-30 [1710610.001]
  • [Cites] Retrovirology. 2006 Oct 17;3:71 [17042961.001]
  • [Cites] Blood. 2016 Dec 15;128(24):2745 [27979862.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):33132-41 [17855372.001]
  • [Cites] Oncogene. 1998 Feb 5;16(5):643-54 [9482110.001]
  • [Cites] Hum Mol Genet. 2003 Jan 15;12(2):87-98 [12499390.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5965-75 [16155603.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] J Virol. 2002 Mar;76(6):2648-53 [11861831.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1980-8 [16263794.001]
  • [Cites] J Virol. 1999 Feb;73(2):1271-7 [9882331.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):166-70 [12545176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6670-5 [9192623.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):221-8 [6088403.001]
  • [Cites] Oncogene. 1999 Sep 30;18(40):5487-96 [10523825.001]
  • [Cites] Immunity. 2005 Jun;22(6):737-48 [15963788.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5996-6004 [16155606.001]
  • [Cites] Virology. 2004 Jan 5;318(1):327-36 [14972558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11612-6 [9326658.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Virology. 2004 Mar 1;320(1):52-62 [15003862.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Retrovirology. 2005 Jul 23;2:46 [16042787.001]
  • [Cites] J Virol. 2007 Nov;81(21):11900-7 [17715223.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(21):8244-53 [11027293.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2349-52 [1766679.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5967-72 [10557085.001]
  • [Cites] Science. 2000 Jul 7;289(5476):113-6 [10884224.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43307-20 [15269214.001]
  • (PMID = 18661220.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Membrane Proteins; 0 / SCRIB protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


36. Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Matsuda T, Tanaka Y, Ohshiro K, Mori N: Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology; 2006;3:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
  • BACKGROUND: Human T-cell leukemia virus type 1 (HTLV-1), the etiologic agent for adult T-cell leukemia (ATL), induces cytokine-independent proliferation of T-cells, associated with the acquisition of constitutive activation of Janus kinases (Jak) and signal transducers and activators of transcription (Stat) proteins.
  • RESULTS: Constitutive activation of Stat3 and Stat5 was observed in HTLV-1-infected T-cell lines and primary ATL cells, but not in HTLV-1-negative T-cell lines.
  • AG490 inhibited the growth of HTLV-1-infected T-cell lines and primary ATL cells by inducing G1 cell-cycle arrest mediated by altering the expression of cyclin D2, Cdk4, p53, p21, Pim-1 and c-Myc, and by apoptosis mediated by the reduced expression of c-IAP2, XIAP, survivin and Bcl-2.
  • [MeSH-minor] Base Sequence. Cell Line. Cell Line, Tumor. DNA Primers. Enzyme Inhibitors / pharmacology. Humans. Leukemia-Lymphoma, Adult T-Cell. Phosphorylation. Protein-Tyrosine Kinases / metabolism. STAT Transcription Factors / metabolism. Signal Transduction. Tyrphostins / pharmacology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8523-30 [14679020.001]
  • [Cites] Oncogene. 2004 Oct 28;23(50):8272-81 [15467747.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] J Exp Med. 1985 Dec 1;162(6):2169-74 [2866223.001]
  • [Cites] Int J Cancer. 1986 Jan 15;37(1):35-42 [3000953.001]
  • [Cites] J Virol. 1989 Aug;63(8):3220-6 [2501514.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):225-31 [2161813.001]
  • [Cites] Int J Cancer. 1990 Oct 15;46(4):675-81 [1698731.001]
  • [Cites] Science. 1995 Jul 7;269(5220):79-81 [7604283.001]
  • [Cites] Annu Rev Biochem. 1995;64:621-51 [7574495.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3619-39 [7579327.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3410-7 [8605359.001]
  • [Cites] Nature. 1996 Feb 15;379(6566):645-8 [8628398.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):511-7 [8700224.001]
  • [Cites] Biol Pharm Bull. 1996 Nov;19(11):1518-20 [8951178.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] J Virol. 1998 May;72(5):4408-12 [9557732.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):63-73 [9874564.001]
  • [Cites] J Immunol. 1999 Jan 15;162(2):1144-9 [9916745.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):3897-904 [10201908.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2667-75 [10348340.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):967-74 [15729715.001]
  • [Cites] Retrovirology. 2005;2:27 [15854229.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):765-72 [16106398.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S11-8 [12528768.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3847-54 [10572100.001]
  • [Cites] Endocrinology. 1999 Dec;140(12):5659-68 [10579330.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2511-22 [10851050.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):823-8 [10929036.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5097-104 [11046040.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1094-102 [11314046.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2055-67 [11360190.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Blood. 2001 Aug 1;98(3):823-9 [11468184.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1524-7 [11823475.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):378-85 [11992406.001]
  • [RetractionIn] Tomita M, Kawakami H, Uchihara JN, Okudaira T, Masuda M, Matsuda T, Tanaka Y, Ohshiro K, Mori N. Retrovirology. 2011;8:1 [21210996.001]
  • (PMID = 16603085.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Enzyme Inhibitors; 0 / STAT Transcription Factors; 0 / STAT3 Transcription Factor; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC1483830
  •  go-up   go-down


37. Harashima N, Tanosaki R, Shimizu Y, Kurihara K, Masuda T, Okamura J, Kannagi M: Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. J Virol; 2005 Aug;79(15):10088-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation.
  • We previously reported that Tax-specific CD8(+) cytotoxic T lymphocytes (CTLs), directed to single epitopes restricted by HLA-A2 or A24, expanded in vitro and in vivo in peripheral blood mononuclear cells (PBMC) from some adult T-cell leukemia (ATL) patients after but not before allogeneic hematopoietic stem cell transplantation (HSCT).
  • [MeSH-major] Epitopes / immunology. Gene Products, tax / immunology. HLA-A Antigens / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / therapy. Stem Cell Transplantation. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Amino Acid Sequence. Coculture Techniques. Human T-lymphotropic virus 1 / immunology. Humans. Leukocytes, Mononuclear. Male. Middle Aged. Molecular Sequence Data. Peptides / genetics. T-Cell Antigen Receptor Specificity. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunogenetics. 1999 Nov;50(3-4):201-12 [10602880.001]
  • [Cites] Immunol Today. 1996 Jun;17(6):261-6 [8962628.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1775-83 [11734593.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] Trends Microbiol. 2004 Jul;12(7):346-52 [15223062.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] J Immunol. 1980 Mar;124(3):1045-9 [6244347.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] J Immunol. 1999 Feb 1;162(3):1765-71 [9973440.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):4994-5004 [10528204.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):128-41 [2891797.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] J Virol. 1992 May;66(5):2928-33 [1373197.001]
  • [Cites] Virology. 1992 Jun;188(2):628-36 [1374983.001]
  • [Cites] J Immunol. 1992 Jul 1;149(1):214-21 [1607654.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1567-73 [8496677.001]
  • [Cites] J Immunol. 1993 Oct 1;151(7):3874-83 [7690819.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):163-75 [8254189.001]
  • [Cites] J Immunol. 1994 Apr 15;152(8):3913-24 [8144960.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):281-5 [8532022.001]
  • [Cites] J Virol. 2000 Oct;74(20):9610-6 [11000233.001]
  • (PMID = 16014972.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Gene Products, tax; 0 / HLA-A Antigens; 0 / Peptides
  • [Other-IDs] NLM/ PMC1181560
  •  go-up   go-down


38. Delebecque F, Combredet C, Gabet AS, Wattel E, Brahic M, Tangy F: A chimeric human T cell leukemia virus type I bearing a deltaR Moloney-murine leukemia virus envelope infects mice persistently and induces humoral and cellular immune responses. J Infect Dis; 2005 Jan 15;191(2):255-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A chimeric human T cell leukemia virus type I bearing a deltaR Moloney-murine leukemia virus envelope infects mice persistently and induces humoral and cellular immune responses.
  • Human T cell lymphotropic virus (HTLV) type I is the agent of adult T cell leukemia and HTLV-I-associated myelopathy.
  • We report the infection of adult BALB/c, C3H/He, 129Sv, and 129Sv IFNAR(-/-) mice with an infectious chimeric HTLV-I provirus bearing the Moloney-murine leukemia virus (Mo-MuLV) envelope glycoprotein truncated for the C-terminal R peptide.
  • [MeSH-major] Chimera / immunology. Human T-lymphotropic virus 1 / immunology. Moloney murine leukemia virus / immunology. Viral Envelope Proteins / immunology
  • [MeSH-minor] Animals. Antibody Formation / immunology. Cell Line. Disease Models, Animal. Humans. Immunity, Cellular / immunology. Mice. Proviruses

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609236.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Viral Envelope Proteins
  •  go-up   go-down


39. Koga Y, Iwanaga M, Soda M, Inokuchi N, Sasaki D, Hasegawa H, Yanagihara K, Yamaguchi K, Kamihira S, Yamada Y: Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan. J Med Virol; 2010 Apr;82(4):668-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan.
  • Most previous studies aimed at estimating the number of human T-cell leukemia virus type-1 (HTLV-1) carriers in endemic areas have been based on seroprevalence rates in blood donors; however, this may result in underestimation because of the healthy donor effect.
  • The incidence of adult T-cell leukemia/lymphoma (ATLL) among HTLV-1 carriers was estimated using data from the Nagasaki Prefectural Cancer Registry.
  • [MeSH-major] HTLV-I Infections / complications. HTLV-I Infections / epidemiology. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / epidemiology. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier State / epidemiology. Child. Child, Preschool. Female. Hospitals. Humans. Incidence. Infant. Infant, Newborn. Japan. Male. Middle Aged. Seroepidemiologic Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20166187.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Ohyashiki JH, Hamamura R, Kobayashi C, Zhang Y, Ohyashiki K: A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells. Adv Appl Bioinform Chem; 2008;1:85-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells.
  • A proteasome inhibitor, bortezomib, could be a potential therapeutic agent in treating adult T-cell leukemia (ATL) patients, however, the underlying mechanism by which bortezomib induces cell death in ATL cells via gene regulatory network has not been fully elucidated.
  • Here we show that a Bayesian statistical framework by VoyaGene(®) identified a secreted protein acidic and rich in cysteine (SPARC) gene, a tumor-invasiveness related gene, as a possible modulator of bortezomib-induced cell death in ATL cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):327-35 [9322895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):728-44 [12930383.001]
  • [Cites] J Dermatol. 2003 Sep;30(9):641-3 [14578552.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2039-46 [15026341.001]
  • [Cites] Nat Biotechnol. 2005 Feb;23(2):238-43 [15654329.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):630-9 [15659509.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):243-53 [15711544.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4467-70 [15930259.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):310-6 [16052522.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):599-608 [16449999.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1099-105 [17895889.001]
  • [Cites] Leukemia. 1998 Jun;12(6):1001 [9639435.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] J Bioinform Comput Biol. 2004 Sep;2(3):533-50 [15359425.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):419-30 [15543232.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):263-8 [16012759.001]
  • [Cites] Bioinformatics. 2006 Apr 1;22(7):815-22 [16418235.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1341-52 [16810203.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):319-25 [17235047.001]
  • [Cites] Oncogene. 2007 Dec 13;26(57):7859-71 [17603561.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3448-52 [8159767.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 21;287(2):422-6 [11554745.001]
  • (PMID = 21918608.001).
  • [ISSN] 1178-6949
  • [Journal-full-title] Advances and applications in bioinformatics and chemistry : AABC
  • [ISO-abbreviation] Adv Appl Bioinform Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3169936
  • [Keywords] NOTNLM ; SPARC / adult T cell leukemia / bortezomib / network biology
  •  go-up   go-down


41. Ching YP, Chan SF, Jeang KT, Jin DY: The retroviral oncoprotein Tax targets the coiled-coil centrosomal protein TAX1BP2 to induce centrosome overduplication. Nat Cell Biol; 2006 Jul;8(7):717-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukaemia virus type I (HTLV-I) is etiologically associated with adult T-cell leukaemia (ATL).
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Centrosome / metabolism. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767081.001).
  • [ISSN] 1465-7392
  • [Journal-full-title] Nature cell biology
  • [ISO-abbreviation] Nat. Cell Biol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ139275
  • [Grant] United States / FIC NIH HHS / TW / R01 TW06186-01; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / VAC14 protein, human
  •  go-up   go-down


42. Washiyama M, Nishigaki K, Ahmed N, Kinpara S, Ishii Y, Kanzawa N, Masuda T, Kannagi M: IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines. FEBS Lett; 2007 Nov 13;581(27):5207-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines.
  • Expression of human T-cell leukemia virus type-1 (HTLV-1) in adult T-cell leukemia (ATL) cells is known to be marginal in vivo and inducible in short-term culture.
  • In this study, we demonstrated that withdrawal of interleukin (IL)-2 from IL-2-dependent ATL cell lines resulted in induction of HTLV-1 mRNA and protein expression, and that viral induction was associated with phosphorylation of the stress kinase p38 and its downstream CREB.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Cyclic AMP Response Element-Binding Protein / metabolism. DNA Primers / genetics. DNA, Viral / genetics. Gene Expression Regulation, Viral / drug effects. Genes, Viral / drug effects. Genes, gag. HTLV-I Antigens / biosynthesis. HTLV-I Antigens / genetics. Humans. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / virology. MAP Kinase Signaling System / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Viral / genetics. RNA, Viral / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950728.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / DNA Primers; 0 / DNA, Viral; 0 / HTLV-I Antigens; 0 / Interleukin-2; 0 / RNA, Messenger; 0 / RNA, Viral; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


43. Jain P, Mostoller K, Flaig KE, Ahuja J, Lepoutre V, Alefantis T, Khan ZK, Wigdahl B: Identification of human T cell leukemia virus type 1 tax amino acid signals and cellular factors involved in secretion of the viral oncoprotein. J Biol Chem; 2007 Nov 23;282(47):34581-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of human T cell leukemia virus type 1 tax amino acid signals and cellular factors involved in secretion of the viral oncoprotein.
  • Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of a number of pathologic abnormalities, including adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
  • Recently, cell-free Tax was detected in the cerebrospinal fluid of HAM/TSP patients, implying that extracellular Tax may be relevant to neurologic disease.
  • Tax was shown to interact with a number of cellular secretory pathway proteins in both the model cell line BHK (baby hamster kidney)-21 and an HTLV-1-infected T cell line, C8166, physiologically relevant to HTLV-1-induced disease.
  • [MeSH-minor] Animals. Cricetinae. Gene Silencing. Humans. Jurkat Cells. Leukemia-Lymphoma, Adult T-Cell / cerebrospinal fluid. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. Paraparesis, Tropical Spastic / cerebrospinal fluid. Paraparesis, Tropical Spastic / genetics. Paraparesis, Tropical Spastic / virology. Protein Structure, Tertiary / physiology. Protein Transport / physiology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897946.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01 CA 054559-13A1; United States / NINDS NIH HHS / NS / NS 044801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Nuclear Export Signals
  •  go-up   go-down


44. Utsunomya A: [Clinical and hematological characteristics of adult T-cell leukemia/lymphoma]. Rinsho Ketsueki; 2006 Dec;47(12):1502-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell
  • [MeSH-minor] Benzamides / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Carrier State / epidemiology. Carrier State / transmission. Cyclohexanones / therapeutic use. HIV Protease Inhibitors / therapeutic use. Human T-lymphotropic virus 1. Humans. Infectious Disease Transmission, Vertical. NF-kappa B / antagonists & inhibitors. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use. Ritonavir / therapeutic use. Stem Cell Transplantation. Transplantation, Homologous

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233468.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Benzamides; 0 / Boronic Acids; 0 / Cyclohexanones; 0 / HIV Protease Inhibitors; 0 / NF-kappa B; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / dehydroxymethylepoxyquinomicin; 69G8BD63PP / Bortezomib; O3J8G9O825 / Ritonavir
  • [Number-of-references] 91
  •  go-up   go-down


45. Hiraragi H, Michael B, Nair A, Silic-Benussi M, Ciminale V, Lairmore M: Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-mediated apoptosis. J Virol; 2005 Aug;79(15):9449-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia.
  • We have demonstrated that proviral clones of HTLV-1 which are mutated in pX ORF II fail to obtain typical proviral loads and antibody responses in a rabbit animal model. p13(II) localizes to mitochondria and reduces cell growth and tumorigenicity in mice, but its function in human lymphocytes remains undetermined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] J Virol. 1997 Jan;71(1):75-83 [8985325.001]
  • [Cites] J Virol. 1998 Mar;72(3):2554-9 [9499124.001]
  • [Cites] J Virol. 1998 May;72(5):4458-62 [9557741.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4505-14 [10442641.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1765-70 [11080824.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1771-6 [11080825.001]
  • [Cites] J Virol. 2000 Dec;74(24):11988-92 [11090202.001]
  • [Cites] Anticancer Drugs. 2001 Mar;12(3):163-84 [11290863.001]
  • [Cites] Methods Enzymol. 2001;333:73-87 [11400356.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1153-60 [11480555.001]
  • [Cites] Virus Res. 2001 Oct 30;78(1-2):35-43 [11520578.001]
  • [Cites] J Virol. 2002 Feb;76(3):1400-14 [11773414.001]
  • [Cites] Lancet Oncol. 2001 Jan;2(1):18-26 [11905614.001]
  • [Cites] Cancer. 2002 Apr 25;96(2):110-6 [11954028.001]
  • [Cites] J Virol. 2002 Aug;76(15):7843-54 [12097596.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34424-33 [12093802.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5775-85 [12477721.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):563-72 [12813136.001]
  • [Cites] J Virol. 2003 Oct;77(20):11027-39 [14512551.001]
  • [Cites] Adv Cancer Res. 2003;89:69-132 [14587871.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):8999-9006 [14663478.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6629-34 [15100416.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26287-99 [15090542.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2556-76 [15358581.001]
  • [Cites] J Virol. 2004 Oct;78(20):11077-83 [15452228.001]
  • [Cites] J Virol. 1992 Mar;66(3):1737-45 [1310774.001]
  • [Cites] J Virol. 1993 Apr;67(4):2360-6 [8445734.001]
  • [Cites] Virology. 1994 Nov 1;204(2):656-64 [7941334.001]
  • [Cites] Immunity. 1995 Apr;2(4):341-51 [7536620.001]
  • [Cites] Virology. 1995 Jun 1;209(2):445-56 [7539968.001]
  • [Cites] J Virol. 1996 Jun;70(6):3599-605 [8648694.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S132-45 [8797716.001]
  • [Cites] Br Med Bull. 1997;53(3):539-53 [9374036.001]
  • (PMID = 16014908.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA092009-02; United States / NCRR NIH HHS / RR / RR014324-05; United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / FIC NIH HHS / TW / R03 TW005705; United States / NCI NIH HHS / CA / CA092009-02; United States / NCRR NIH HHS / RR / R01 RR14324; United States / NCI NIH HHS / CA / P01 CA100730-03; United States / FIC NIH HHS / TW / TW05705; United States / NCRR NIH HHS / RR / R01 RR014324; United States / NCI NIH HHS / CA / CA100730-03; United States / NCRR NIH HHS / RR / R01 RR014324-05; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retroviridae Proteins; 0 / rof protein, Human T-lymphotropic virus 1; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC1181595
  •  go-up   go-down


46. Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R: Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer; 2006 Jun 15;118(12):3054-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.
  • Patients with adult T-cell leukemia/lymphoma (ATLL) are in a severely immunocompromised state.
  • We examined the levels of serum cytokines including T helper type 1- (Th1-) associated cytokines [IFN-gamma, TNF-alpha, and interleukin (IL)-2], Th2-associated cytokines (IL-4, -5 and -6) and regulatory T cell-associated cytokines (IL-10 and TGF-beta1) in 94 ATLL patients, 39 asymptomatic human T-cell lymphotropic virus type-1 (HTLV-1) carriers and 50 healthy adult volunteers, to clarify whether elevated levels of particular cytokines are associated with the prognosis of ATLL patients.
  • The IL-10 level significantly increased with disease progression at each step from asymptomatic HTLV-1 carrier to ATLL of the indolent variant (chronic and smoldering subtypes) to ATLL of the aggressive variant (acute and lymphoma subtypes).
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin-10 / blood. Interleukin-5 / blood. Leukemia, T-Cell / immunology. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Interferon-gamma / blood. Interleukin-2 / blood. Interleukin-4 / blood. Interleukin-6 / blood. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Transforming Growth Factor beta / blood. Tumor Necrosis Factor-alpha / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16425276.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-2; 0 / Interleukin-5; 0 / Interleukin-6; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


47. Takizawa J, Aoki S, Kurasaki T, Higashimura M, Honma K, Kitajima T, Momoi A, Takahashi H, Nakamura N, Furukawa T, Aizawa Y: Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation. Am J Hematol; 2007 Dec;82(12):1113-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation.
  • This study reports the first well-documented case of adult T-cell leukemia (ATL) successfully treated with unrelated cord blood transplantation (UCBT).
  • A 49-year-old woman was diagnosed with acute-type of ATL.
  • Chemotherapy induced complete remission, but the human T-cell leukemia virus type 1 (HTLV-1) proviral load was detected in mononuclear cells of her peripheral blood.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696205.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


48. Tabata R, Tabata C, Namiuchi S, Terada M, Yasumizu R, Okamoto T, Nagai T: Adult T-cell lymphoma mimicking Henoch-Schönlein purpura. Mod Rheumatol; 2007;17(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell lymphoma mimicking Henoch-Schönlein purpura.
  • We report a male patient with adult T-cell lymphoma, who was initially diagnosed clinically as having Henoch-Schönlein purpura (HSP) with abdominal pain and specific purpura.
  • Adult T-cell lymphoma-like cells were minimal and abdominal lymph nodes were transiently swollen, and the symptoms were improved by supportive management.
  • This rare case suggests the importance of skin biopsies to seek the underlying pathology in adult HSP.

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278024.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Lausen J, Pless O, Leonard F, Kuvardina ON, Koch B, Leutz A: Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1. J Biol Chem; 2010 Feb 19;285(8):5338-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Tal1 transcription factor is essential for the development of the hematopoietic system and plays a role during definitive erythropoiesis in the adult.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Erythrocytes / metabolism. Erythroid Precursor Cells / metabolism. Erythropoiesis / physiology. Gene Expression Regulation, Enzymologic / physiology. Proto-Oncogene Proteins / metabolism. Ubiquitin-Conjugating Enzymes / biosynthesis
  • [MeSH-minor] Antigens, CD34. Cell Differentiation / physiology. Humans. K562 Cells. Ubiquitin / genetics. Ubiquitin / metabolism. Ubiquitination / physiology

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1439-52 [14749362.001]
  • [Cites] Blood. 1996 Jan 1;87(1):102-11 [8547631.001]
  • [Cites] FEBS Lett. 1995 Dec 18;377(2):193-6 [8543049.001]
  • [Cites] EMBO J. 1996 Aug 15;15(16):4123-9 [8861941.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3145-57 [9214632.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):473-9 [9472016.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7030-7 [9507011.001]
  • [Cites] Development. 1999 Oct;126(20):4603-15 [10498694.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):588-95 [15558010.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Mol Cell Proteomics. 2004 May;3(5):501-9 [14963112.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Vox Sang. 2004 Jul;87 Suppl1:15-9 [15200597.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] EMBO J. 2004 Jul 21;23(14):2841-52 [15215894.001]
  • [Cites] Science. 1982 Feb 19;215(4535):978-80 [7156977.001]
  • [Cites] Gene. 1985;35(3):321-31 [3899863.001]
  • [Cites] Blood. 1988 Apr;71(4):1153-6 [2833326.001]
  • [Cites] Adv Exp Med Biol. 1991;307:191-205 [1666814.001]
  • [Cites] Biotechnology (N Y). 1993 Oct;11(10):1138-43 [7764094.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1200-8 [8118024.001]
  • [Cites] J Biol Chem. 1994 Mar 25;269(12):8797-802 [8132613.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):432-4 [7830794.001]
  • [Cites] Blood. 1995 Feb 1;85(3):675-84 [7833471.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9507-16 [7721879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):4982-6 [7761435.001]
  • [Cites] Blood. 1995 Jul 15;86(2):666-76 [7605997.001]
  • [Cites] Curr Biol. 1995 Aug 1;5(8):909-22 [7583149.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12956-66 [15677454.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(15):6355-62 [16024775.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):369-81 [16633365.001]
  • [Cites] Dev Biol. 2006 Jun 15;294(2):525-40 [16626682.001]
  • [Cites] Blood. 2006 Aug 1;108(3):986-92 [16621969.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1511-8 [16926849.001]
  • [Cites] J Mol Cell Cardiol. 2006 Oct;41(4):567-79 [16949602.001]
  • [Cites] Biochem J. 2006 Oct 15;399(2):297-304 [16800816.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2998-3004 [16849639.001]
  • [Cites] Blood Cells Mol Dis. 2006 Nov-Dec;37(3):210-7 [16978890.001]
  • [Cites] Physiol Genomics. 2006 Dec 13;28(1):114-28 [16940433.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2704-7 [17616641.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3005-14 [18184866.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1658-62 [18436863.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1056-67 [18550854.001]
  • [Cites] Nucleic Acids Res. 2008 Sep;36(16):5221-31 [18684996.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D755-61 [18996895.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2191-201 [19011221.001]
  • [Cites] Nat Biotechnol. 2009 Mar;27(3):264-74 [19234449.001]
  • [Cites] Blood. 2009 May 28;113(22):5456-65 [19346495.001]
  • [Cites] Exp Hematol. 2009 Oct;37(10):1143-1156.e3 [19607874.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1193-207 [10582347.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2248-59 [10688671.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6792-803 [11118214.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):57-64 [11262875.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):373-428 [11917093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]
  • [Cites] Genome Res. 2002 Apr;12(4):656-64 [11932250.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18365-72 [11904294.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3368-76 [12032775.001]
  • [Cites] Exp Hematol. 2002 Jul;30(7):634-9 [12135659.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):547-51 [12540851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7 [12552125.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1048-57 [12773487.001]
  • [Cites] Nat Immunol. 2003 Jul;4(7):607-15 [12830135.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] Trends Cardiovasc Med. 2003 Aug;13(6):254-9 [12922023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11842-9 [14504387.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):11-24 [14725896.001]
  • (PMID = 20028976.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / Ubiquitin; 135471-20-4 / TAL1 protein, human; EC 6.3.2.19 / UBE2H protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  • [Other-IDs] NLM/ PMC2820762
  •  go-up   go-down


50. Durkin SS, Guo X, Fryrear KA, Mihaylova VT, Gupta SK, Belgnaoui SM, Haoudi A, Kupfer GM, Semmes OJ: HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase. J Biol Chem; 2008 Dec 26;283(52):36311-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type-1 is the causative agent for adult T-cell leukemia.
  • Previous research has established that the viral oncoprotein Tax mediates the transformation process by impairing cell cycle control and cellular response to DNA damage.

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5836-48 [12897153.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37736-44 [12842897.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6008-15 [14522929.001]
  • [Cites] Carcinogenesis. 2003 Oct;24(10):1571-80 [12919958.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1496-501 [14571772.001]
  • [Cites] Am J Pathol. 1985 Sep;120(3):464-77 [2412448.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1082-4 [2309119.001]
  • [Cites] Blood. 1992 Aug 15;80(4):1012-6 [1498321.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5041-9 [1406679.001]
  • [Cites] Virology. 1993 Mar;193(1):456-9 [8438579.001]
  • [Cites] J Biol Chem. 1996 Apr 12;271(15):8936-41 [8621537.001]
  • [Cites] J Virol. 1996 Sep;70(9):6347-57 [8709263.001]
  • [Cites] EMBO J. 1997 Aug 15;16(16):5098-112 [9305651.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3881-90 [17353268.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):713-24 [17634426.001]
  • [Cites] J Biol Chem. 2007 Oct 5;282(40):29431-40 [17698850.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 1;31(23):6819-27 [14627815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1247-52 [14734805.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2390-6 [15059890.001]
  • [Cites] Immunol Rev. 2004 Aug;200:132-41 [15242401.001]
  • [Cites] Int J Oncol. 2004 Aug;25(2):461-8 [15254745.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):909-18 [15279776.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2495-9 [15353302.001]
  • [Cites] J Biol Chem. 2004 Sep 17;279(38):39408-13 [15258142.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3377-86 [10779327.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32906-10 [10969065.001]
  • [Cites] J Virol. 2001 Jan;75(1):396-407 [11119608.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):247-54 [11242102.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):225-31 [11248557.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(11):3642-51 [11340158.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3612-20 [11369658.001]
  • [Cites] Curr Biol. 2001 Nov 13;11(22):R920-4 [11719239.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15084-8 [11742099.001]
  • [Cites] J Hum Genet. 2001;46(12):706-11 [11776383.001]
  • [Cites] Science. 2002 Jul 26;297(5581):547-51 [12142523.001]
  • [Cites] Genes Dev. 2002 Sep 15;16(18):2333-8 [12231622.001]
  • [Cites] Biochemistry. 2002 Oct 22;41(42):12706-14 [12379113.001]
  • [Cites] EMBO J. 2002 Nov 15;21(22):6275-87 [12426399.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Virology. 2003 Jan 20;305(2):229-39 [12573569.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):155-68 [12612651.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24097-100 [9305850.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):483-6 [9398856.001]
  • [Cites] J Virol. 1998 Aug;72(8):6348-55 [9658074.001]
  • [Cites] Mol Cell. 1998 Jul;2(1):1-8 [9702186.001]
  • [Cites] Virology. 1999 Jan 20;253(2):155-61 [9918874.001]
  • [Cites] Exp Cell Res. 1999 Mar 15;247(2):525-33 [10066380.001]
  • [Cites] J Virol. 1999 May;73(5):4299-304 [10196328.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):916-34 [10215620.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):933-42 [10359545.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Dec;311(3):1062-70 [15273254.001]
  • [Cites] Am J Hematol. 2005 Feb;78(2):100-7 [15682421.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):949-61 [15592499.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):12041-50 [15668230.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14709-15 [15677476.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):864-70 [15829956.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Retrovirology. 2005;2:45 [16014171.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] Cancer Lett. 2005 Nov 18;229(2):171-9 [16129552.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):10842-52 [16314509.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):438-47 [16158050.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):974-83 [16585963.001]
  • [Cites] J Cell Biol. 2006 Apr 24;173(2):195-206 [16618811.001]
  • [Cites] Nucleic Acids Res. 2006;34(8):2408-17 [16682448.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1042-8 [16822724.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31705-12 [16923801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18137-42 [17110439.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):11950-9 [17272270.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):219-29 [17438073.001]
  • [Cites] Oncogene. 2003 Jun 12;22(24):3734-41 [12802280.001]
  • [Cites] Immunol Rev. 2003 Aug;194:77-95 [12846809.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • (PMID = 18957425.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA076595; United States / NCI NIH HHS / CA / CA-76595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Gene Products, tax; 0 / Ku autoantigen; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2605996
  •  go-up   go-down


51. Pichler K, Kattan T, Gentzsch J, Kress AK, Taylor GP, Bangham CR, Grassmann R: Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein. Blood; 2008 May 1;111(9):4741-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1), the cause of adult T-cell leukemia, stimulates the growth of infected T cells in cultures and in nonleukemic patients.
  • In the latter, HTLV-1 is found in long-term persisting T-cell clones.
  • Up-regulated 4-1BB expression was a consistent feature of all HTLV-1-infected cell lines, whether patient-derived or in vitro transformed.
  • The ligand of 4-1BB was also found on transformed T-cell lines, opening up the possibility of autostimulation.
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Clone Cells / virology. Human T-lymphotropic virus 1. Humans. NF-kappa B. Up-Regulation

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18276843.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD137; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / TNFRSF9 protein, human
  •  go-up   go-down


52. Semmes OJ, Cazares LH, Ward MD, Qi L, Moody M, Maloney E, Morris J, Trosset MW, Hisada M, Gygi S, Jacobson S: Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia; 2005 Jul;19(7):1229-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human T-cell leukemia virus type I (HTLV-I) is the causative agent for adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
  • [MeSH-major] Blood Proteins / analysis. Leukemia-Lymphoma, Adult T-Cell / blood. Paraparesis, Tropical Spastic / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Regression Analysis. Reproducibility of Results. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889159.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


53. Terme JM, Wencker M, Favre-Bonvin A, Bex F, Gazzolo L, Duc Dodon M, Jalinot P: Cross talk between expression of the human T-cell leukemia virus type 1 Tax transactivator and the oncogenic bHLH transcription factor TAL1. J Virol; 2008 Aug;82(16):7913-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross talk between expression of the human T-cell leukemia virus type 1 Tax transactivator and the oncogenic bHLH transcription factor TAL1.
  • The human T-cell leukemia virus type 1 (HTLV-1) Tax transactivator is known to induce or repress various cellular genes, several of them encoding transcription factors.
  • As Tax is known to deregulate various basic bHLH factors, we looked more specifically at its effect on TAL1 (T-cell acute lymphoblastic leukemia 1), also known as SCL (stem cell leukemia).
  • Indeed, TAL1 is deregulated in a high percentage of T-cell acute lymphoblastic leukemia cells, and its oncogenic properties are well-established.
  • These data show the existence of a positive feedback loop between Tax and TAL1 expression and support the notion that this proto-oncogene participates in generation of adult T-cell leukemia/lymphoma by increasing the amount of the Tax oncoprotein but also possibly by its own transforming activities.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Gene Expression Regulation, Viral. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / virology. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Binding Sites. Cell Line. Feedback, Physiological. HeLa Cells. Humans. Models, Biological. NF-kappa B / metabolism. Promoter Regions, Genetic. Thymus Gland / cytology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Apr 7;275(14):10551-60 [10744749.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3327-38 [11971966.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):11-24 [14725896.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1439-52 [14749362.001]
  • [Cites] J Cell Sci. 2004 Mar 1;117(Pt 7):1161-71 [14970264.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2662-72 [15024057.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Lancet. 1986 Sep 20;2(8508):698 [2876179.001]
  • [Cites] Science. 1996 Aug 16;273(5277):951-3 [8688078.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3662-7 [9108034.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2392-405 [9528808.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3620-32 [9584203.001]
  • [Cites] J Virol. 1999 Jan;73(1):738-45 [9847380.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4958-67 [10490830.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1082-4 [2309119.001]
  • [Cites] Genes Dev. 1990 Nov;4(11):1875-85 [2276622.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1327-33 [1311214.001]
  • [Cites] Blood. 1992 Sep 15;80(6):1511-20 [1387813.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2110-7 [8471769.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4269-78 [8223437.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8617-21 [8078932.001]
  • [Cites] Blood. 1995 Feb 1;85(3):675-84 [7833471.001]
  • [Cites] J Mol Biol. 1995 Jul 7;250(2):169-80 [7608968.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9585-9 [7568177.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2174-82 [8628284.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2248-59 [10688671.001]
  • [Cites] J Virol. 2004 Dec;78(24):13848-64 [15564493.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):525-40 [15580311.001]
  • [Cites] J Virol. 2005 Jul;79(14):9346-50 [15994832.001]
  • [Cites] Virology. 2005 Aug 15;339(1):1-11 [15964046.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] J Mol Biol. 2006 Jan 6;355(1):9-19 [16298389.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6008-13 [16778171.001]
  • [Cites] Blood. 2006 Aug 1;108(3):986-92 [16621969.001]
  • [Cites] J Virol. 2007 Jan;81(1):301-8 [17050604.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(7):2687-97 [17242194.001]
  • [Cites] J Virol. 2001 Oct;75(20):9885-95 [11559821.001]
  • (PMID = 18495761.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins; 0 / tax protein, Human T-lymphotrophic virus 1; 135471-20-4 / TAL1 protein, human
  • [Other-IDs] NLM/ PMC2519563
  •  go-up   go-down


54. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood; 2008 Feb 1;111(3):1060-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia.
  • Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Histone Deacetylase Inhibitors. Hydroxamic Acids / therapeutic use. Leukemia / drug therapy. Leukemia / pathology. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Acetylation. Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials, Phase I as Topic. Dose-Response Relationship, Drug. Drug Tolerance. Drug-Related Side Effects and Adverse Reactions. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Histone Deacetylases / metabolism. Histones / metabolism. Humans. Male. Middle Aged. Neoplasm Staging


55. Khadilkar UN, Mathai AM, Chakrapani M, Prasad K: Rare association of papillary carcinoma of thyroid with adult T-cell lymphoma/leukemia. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):125-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare association of papillary carcinoma of thyroid with adult T-cell lymphoma/leukemia.
  • We report a rare association of papillary carcinoma of thyroid in an elderly lady with adult T-cell lymphoma/leukemia.
  • Fine needle aspiration of the thyroid, neck nodes and evaluation of the bone marrow and peripheral blood helped in the diagnosis of papillary cancer coexisting with adult T-cell lymphoma/leukemia.
  • [MeSH-major] Carcinoma, Papillary / complications. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Thyroid Gland / pathology. Thyroid Neoplasms / complications
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Bone Marrow / pathology. Female. Histocytochemistry. Humans. Immunohistochemistry. Leukemia. Middle Aged. Neck / radiography. Thyroid Nodule. Tomography

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090241.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


56. Malan R, Berini CA, Eirin ME, Delfino CM, Pedrozo W, Krupp R, García Plichta A, Biglione MM: [Seroprevalence of HTLV-1/2 in blood donors from Misiones Province]. Medicina (B Aires); 2010;70(1):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell Lymphotropic viruses type 1 (HTLV-1), the first human oncoretrovirus to be discovered, is the etiologic agent of Adult T-cell Leukemia (ATL) and HTLV-1 Associated Mielopathy or Tropical Spastic Paraparesis (HAM/TSP).
  • [MeSH-minor] Adult. Argentina / epidemiology. Enzyme-Linked Immunosorbent Assay. Female. Human T-lymphotropic virus 1 / isolation & purification. Human T-lymphotropic virus 2 / isolation & purification. Humans. Male. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228028.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


57. Primo J, Siqueira I, Nascimento MC, Oliveira MF, Farre L, Carvalho EM, Bittencourt AL: High HTLV-1 proviral load, a marker for HTLV-1 associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1. Braz J Med Biol Res; 2009 Aug;42(8):761-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salvador (BA, Brazil) is an endemic area for human T-cell lymphotrophic virus type 1 (HTLV-1).
  • HTLV-1 carriers may develop a variety of diseases such as adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and infective dermatitis associated with HTLV-1 (IDH).
  • The replication of HTLV-1 has been reported to be greater in adult HAM/TSP patients than in asymptomatic HTLV-1 carriers.
  • In the current study, the proviral load of 28 children and adolescents with IDH not associated with HAM/TSP was determined and the results were compared to those obtained in 28 HTLV-1 adult carriers and 28 adult patients with HAM/TSP.

  • Genetic Alliance. consumer health - Spastic paraparesis.
  • Genetic Alliance. consumer health - Tropical spastic paraparesis.
  • Genetic Alliance. consumer health - HTLV-1 associated myelopathy/tropical spastic paraparesis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1998 Apr;134(4):439-44 [9554295.001]
  • [Cites] J Neurovirol. 1998 Dec;4(6):586-93 [10065900.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):691-700 [10365395.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):e90-6 [15889351.001]
  • [Cites] Clin Infect Dis. 2005 Aug 15;41(4):535-41 [16028164.001]
  • [Cites] J Infect Dis. 2006 Sep 1;194(5):552-60 [16897651.001]
  • [Cites] Lancet. 1991 Dec 21-28;338(8782-8783):1593-4 [1683991.001]
  • [Cites] Pediatr Infect Dis J. 2000 Jun;19(6):560-5 [10877174.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4954-60 [11042682.001]
  • [Cites] J Virol Methods. 2002 Apr;102(1-2):37-51 [11879691.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):527-31 [14657765.001]
  • [Cites] J Infect Dis. 2004 Jan 1;189(1):41-5 [14702151.001]
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):440-2 [18173359.001]
  • (PMID = 19578703.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW007127; United States / FIC NIH HHS / TW / TW007127-05; United States / FIC NIH HHS / TW / D43 TW007127-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS241997; NLM/ PMC2963476
  •  go-up   go-down


58. Chlichlia K, Khazaie K: HTLV-1 Tax: Linking transformation, DNA damage and apoptotic T-cell death. Chem Biol Interact; 2010 Nov 5;188(2):359-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 Tax: Linking transformation, DNA damage and apoptotic T-cell death.
  • The human T-cell leukemia virus type I (HTLV-1) is the causative agent of adult T-cell leukemia (ATL), an aggressive CD4-positive T-cell neoplasia.
  • During the course of HTLV-1 infection, the dysregulation of cell-cycle checkpoints and the suppression of DNA damage repair is tightly linked to the activity of the viral oncoprotein Tax.
  • Tax activity is associated with production of reactive oxygen intermediates (ROS), chromosomal instability and DNA damage, apoptotic cell death and cellular transformation.
  • [MeSH-major] Apoptosis. Cell Transformation, Viral. DNA Damage. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. T-Lymphocytes / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20558150.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / tax protein, Human T-lymphotrophic virus 1
  •  go-up   go-down


59. Pise-Masison CA, Brady JN: Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. Front Biosci; 2005 Jan 1;10:919-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-lymphotropic virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia and tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM).
  • Tax has been shown to regulate viral and cellular gene expression and to functionally interfere with proteins involved in cell-cycle progression and DNA repair.
  • This review will concentrate on the ability of Tax to promote cellular proliferation through activation of the NF-kappaB pathway while inhibiting the cell-cycle checkpoint and apoptotic function of the tumor suppressor gene p53.
  • [MeSH-major] Cell Transformation, Neoplastic. Gene Products, tax / chemistry. Human T-lymphotropic virus 1 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Animals. Cell Cycle. Cell Proliferation. DNA Repair. Humans. NF-kappa B / metabolism. Terminal Repeat Sequences

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15569630.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / NF-kappa B; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 155
  •  go-up   go-down


60. Biagi E, Marin V, Giordano Attianese GM, Dander E, D'Amico G, Biondi A: Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica; 2007 Mar;92(3):381-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
  • Chimeric T-cell receptors (ChTCR), are a fascinating technological step in the field of immunotherapy for orienting the activity of immune cells towards specific molecular targets expressed on the cell surface of various tumors, including hematologic malignancies.
  • The main characteristics of ChTCR are their ability to redirect T-cell specificity and their killing/effector activity toward a selected target in a non MHC-restricted manner, exploiting the antigen binding properties of monoclonal antibodies.
  • ChTCR are, in fact, artificial T-cell receptors constituted by an antigen-recognizing antibody molecule linked to a T-cell triggering domain.
  • Thus, CD19 and CD20 have been targeted for B-cell lymphoid tumors (acute lymphoblastic leukemia-ALL, lymphomas and chronic lymphocytic leukemia-CLL), CD33 for myeloid leukemia, and CD30 for lymphomas.
  • [MeSH-major] Antigens, Neoplasm / immunology. Immunotherapy / methods. Neoplasms / therapy. Receptors, Antigen, T-Cell / immunology. Recombinant Fusion Proteins / immunology
  • [MeSH-minor] Adult. Animals. Antigens, CD / immunology. Antigens, CD19 / immunology. Antigens, CD20 / immunology. Antigens, CD30 / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Child. Clinical Trials as Topic. Drug Delivery Systems. Forecasting. Hematologic Neoplasms / therapy. Humans. Killer Cells, Natural / immunology. Sialic Acid Binding Ig-like Lectin 3. T-Cell Antigen Receptor Specificity. T-Lymphocytes, Cytotoxic / immunology

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339188.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD33 protein, human; 0 / Receptors, Antigen, T-Cell; 0 / Recombinant Fusion Proteins; 0 / Sialic Acid Binding Ig-like Lectin 3
  • [Number-of-references] 64
  •  go-up   go-down


61. Bonnefoix T, Callanan M: Challenging the adult T-cell leukemia/lymphoma (ATL) stem cell concept based on limiting dilution transplantation assay. Blood; 2010 Mar 11;115(10):2117-8; author reply 2118
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging the adult T-cell leukemia/lymphoma (ATL) stem cell concept based on limiting dilution transplantation assay.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Animals. Antigens, CD / metabolism. Antigens, CD38 / metabolism. Cell Separation / methods. Genes, pX. Humans. Membrane Glycoproteins / metabolism. Mice. Mice, Transgenic. Neoplasm Transplantation / methods. Proto-Oncogene Proteins c-kit / metabolism. Receptors, Transferrin / metabolism. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2009 Sep 24;114(13):2709-20 [19584402.001]
  • (PMID = 20223932.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Evaluation Studies; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD71 antigen; 0 / Membrane Glycoproteins; 0 / Receptors, Transferrin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / Cd38 protein, mouse
  •  go-up   go-down


62. Yano H, Ishida T, Imada K, Sakai T, Ishii T, Inagaki A, Iida S, Uchiyama T, Ueda R: Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol; 2008 Mar;140(5):586-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / therapy. Receptors, CCR4 / immunology
  • [MeSH-minor] Adult. Animals. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Mice. Mice, SCID

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3625-34 [14506150.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2127-33 [15026353.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1659-69 [15210744.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Leukemia. 2006 Dec;20(12):2162-8 [17039235.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7529-39 [15569983.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1139-46 [16952304.001]
  • [Cites] Jpn J Cancer Res. 1996 Sep;87(9):887-92 [8878449.001]
  • (PMID = 18205860.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / CCR4 protein, human; 0 / Receptors, CCR4; 134088-74-7 / nartograstim; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC2268953
  •  go-up   go-down


63. Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H, Amet T, Arai A, Miura O, Yamamoto N, Yamaoka S: Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp Cell Res; 2009 Jan 15;315(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role for protein geranylgeranylation in adult T-cell leukemia cell survival.
  • Adult T-cell leukemia (ATL) is a fatal lymphoproliferative disease that develops in human T-cell leukemia virus type I (HTLV-I)-infected individuals.
  • Here, we report that statins hinder the survival of ATL cells and induce apoptotic cell death.
  • Inhibition of protein geranylgeranylation is responsible for these effects, since simultaneous treatment with isoprenoid precursors, geranylgeranyl pyrophosphate or farnesyl pyrophosphate, but not a cholesterol precursor squalene, restored the viability of ATL cells.
  • Simvastatin inhibited geranylgeranylation of small GTPases Rab5B and Rac1 in ATL cells, and a geranylgeranyl transferase inhibitor GGTI-298 reduced ATL cell viability more efficiently than a farnesyl transferase inhibitor FTI-277.
  • These results not only unveil an important role for protein geranylgeranylation in ATL cell survival, but also implicate therapeutic potentials of statins in the treatment of ATL.
  • [MeSH-minor] Adult. Benzamides / pharmacology. Caspase 3 / metabolism. Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Survival / drug effects. Cell Survival / physiology. Enzyme Inhibitors / pharmacology. Humans. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. I-kappa B Proteins / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Methionine / analogs & derivatives. Methionine / pharmacology. NF-kappa B / metabolism. Phosphorylation / drug effects. Polyisoprenyl Phosphates / pharmacology. Sesquiterpenes / pharmacology. rab5 GTP-Binding Proteins / metabolism. rac1 GTP-Binding Protein / metabolism

  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992741.001).
  • [ISSN] 1090-2422
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Enzyme Inhibitors; 0 / FTI 277; 0 / GGTI 298; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Polyisoprenyl Phosphates; 0 / RAC1 protein, human; 0 / Sesquiterpenes; 139874-52-5 / NF-kappaB inhibitor alpha; 6699-20-3 / geranylgeranyl pyrophosphate; 79W6B01D07 / farnesyl pyrophosphate; AE28F7PNPL / Methionine; EC 3.4.22.- / Caspase 3; EC 3.6.5.2 / rab5 GTP-Binding Proteins; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


64. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • RESULTS: In total, 243 patients with B-precursor and T-cell ALL were treated according to the protocols.
  • There was a significant difference in the remission rate between the NOPHO-92 protocol (99%; n = 144 patients) and the Adult protocol (90%; n = 99 patients; P < .01), and the event-free survival (EFS) was also superior for the NOPHO-92 protocol compared with the Adult protocol (P < .01).
  • However, EFS was higher for patients aged 15 years to 25 years compared with patients aged 26 years to 40 years within the Adult protocol group (P = .01).
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Prognosis. Survival Analysis. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Gallo RC: The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology; 2005;2:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These efforts finally yielded success following the discovery of IL-2 and its use to culture adult T cell lymphoma/leukemia cells.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Human T-lymphotropic virus 2 / isolation & purification. Leukemia, T-Cell / history. Lymphoma, T-Cell / history

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1970 Jun 27;226(5252):1209-11 [4316300.001]
  • [Cites] Virology. 1981 Jul 15;112(1):355-60 [6166122.001]
  • [Cites] J Mol Biol. 1970 Sep 14;52(2):195-219 [5274398.001]
  • [Cites] Nat New Biol. 1972 Feb 9;235(58):170-1 [4501200.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):268-71 [6272125.001]
  • [Cites] Nature. 1981 Nov 19;294(5838):273-5 [6272127.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4738-9 [6975656.001]
  • [Cites] J Exp Med. 1981 Dec 1;154(6):1957-64 [6274993.001]
  • [Cites] Nat New Biol. 1972 Nov 15;240(98):67-72 [4117890.001]
  • [Cites] Biochem Biophys Res Commun. 1974 Apr 8;57(3):934-48 [4133312.001]
  • [Cites] J Natl Cancer Inst. 1974 Dec;53(6):1583-8 [4436864.001]
  • [Cites] J Biol Chem. 1975 Mar 10;250(5):1702-9 [46229.001]
  • [Cites] Bibl Haematol. 1975;(40):59-66 [51637.001]
  • [Cites] Nature. 1970 Jun 27;226(5252):1211-3 [4316301.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] J Immunol. 1982 Mar;128(3):1122-7 [6976987.001]
  • [Cites] Lancet. 1982 Mar 20;1(8273):683 [6121990.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Science. 1982 Nov 5;218(4572):571-3 [6981847.001]
  • [Cites] Nature. 1982 Nov 4;300(5887):63-6 [6982418.001]
  • [Cites] Science. 1982 Feb 19;215(4535):975-8 [6760397.001]
  • [Cites] Science. 1983 Feb 18;219(4586):856-9 [6600519.001]
  • [Cites] EMBO J. 1986 Sep;5(9):2163-70 [3023059.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] J Biol Chem. 1967 Nov 10;242(21):5059-68 [6058946.001]
  • [Cites] J Biol Chem. 1968 Oct 10;243(19):4936-42 [5679973.001]
  • [Cites] J Biol Chem. 1968 Oct 10;243(19):4943-51 [5679974.001]
  • [Cites] Science. 1972 May 19;176(4036):798-800 [4113240.001]
  • [Cites] Proc Natl Acad Sci U S A. 1972 Nov;69(11):3228-32 [4117771.001]
  • [Cites] Acta Haematol. 1975;54(4):201-9 [52980.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Oct;72(10):4137-41 [172897.001]
  • [Cites] Science. 1976 Sep 10;193(4257):1007-8 [181845.001]
  • [Cites] J Immunol. 1977 Jul;119(1):131-8 [141483.001]
  • [Cites] Biochemistry. 1977 Jun 28;16(13):2874-80 [69438.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Nature. 1977 Nov 24;270(5635):347-9 [271272.001]
  • [Cites] Virology. 1978 Feb;84(2):359-73 [74897.001]
  • [Cites] Int J Cancer. 1979 Nov 15;24(5):616-23 [316807.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Mar;78(3):1887-91 [6262827.001]
  • [Cites] J Virol. 1981 Jun;38(3):906-15 [6264163.001]
  • [CommentIn] Retrovirology. 2005;2:15 [15743525.001]
  • (PMID = 15743526.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC555587
  •  go-up   go-down


66. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, Ogata M, Kikuchi H, Sagara Y, Uozumi K, Mochizuki M, Tsukasaki K, Saburi Y, Yamamura M, Tanaka J, Moriuchi Y, Hino S, Kamihira S, Yamaguchi K, Joint Study on Predisposing Factors of ATL Development investigators: Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood; 2010 Aug 26;116(8):1211-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.
  • Definitive risk factors for the development of adult T-cell leukemia (ATL) among asymptomatic human T-cell leukemia virus type I (HTLV-1) carriers remain unclear.
  • [MeSH-major] HTLV-I Infections / virology. Human T-lymphotropic virus 1 / genetics. Leukemia-Lymphoma, Adult T-Cell / epidemiology. Leukemia-Lymphoma, Adult T-Cell / virology. Proviruses / genetics. Viral Load / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / analysis. Blotting, Southern. Carrier State. Child. DNA, Viral / genetics. Disease Progression. Female. Follow-Up Studies. Humans. Japan / epidemiology. Male. Middle Aged. Prognosis. Prospective Studies. Young Adult

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448111.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral
  •  go-up   go-down


67. Duval A, Rivet J, Moulonguet I, Cassar O, Agbalika F, Wallach D, Gessain A, Petit A: Atypical presentation of adult T-cell leukaemia/lymphoma due to HTLV-1: prurigo nodularis lasting twelve years followed by an acute micropapular eruption. Acta Derm Venereol; 2010 May;90(3):287-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentation of adult T-cell leukaemia/lymphoma due to HTLV-1: prurigo nodularis lasting twelve years followed by an acute micropapular eruption.
  • Human T-cell lymphotropic virus type 1 (HTLV-1) causes adult T-cell leukaemia/lymphoma.
  • A 52-year-old black man, from the French West Indies, who had had prurigo nodularis for 12 years, presented with a distinct micropapular eruption with the typical pathological picture of epidermotropic T-cell lymphoma.
  • Based on HTLV-1-positive serology and monoclonal integration of HTLV-1 we diagnosed smouldering adult T-cell leukaemia/lymphoma.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / virology. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Prurigo / virology. Skin / virology

  • Genetic Alliance. consumer health - Prurigo nodularis.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526548.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / IL2RA protein, human; 0 / Interferon-alpha; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Recombinant Proteins; 4B9XT59T7S / Zidovudine; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


68. Naresh KN, Marks AJ: Peripheral blood and bone marrow morphology in adult T-cell leukaemia/lymphoma. Am J Hematol; 2010 Jul;85(7):518
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood and bone marrow morphology in adult T-cell leukaemia/lymphoma.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575019.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


69. Miyazawa T, Aida S, Shima K: Hemorrhagic cerebellar anaplastic glioma appearing 12 years after prophylactic cranial radiotherapy for acute lymphocytic leukemia. Neurol Med Chir (Tokyo); 2008 Mar;48(3):126-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemorrhagic cerebellar anaplastic glioma appearing 12 years after prophylactic cranial radiotherapy for acute lymphocytic leukemia.
  • We report a rare case of hemorrhagic cerebellar anaplastic glioma occurring 12 years after prophylactic cranial radiotherapy for acute lymphocytic leukemia.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Glioma / etiology. Intracranial Hemorrhages / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Anaplasia / etiology. Anaplasia / pathology. Humans. Male. Radiotherapy / adverse effects. Time Factors

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18362460.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Xie F, Wang Q, Chen Y, Gu Y, Mao H, Zeng W, Zhang X: Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract; 2010 Nov 15;206(11):735-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies indicate that OX40/OX40L system mediates the adhesion and infiltration of adult T cell leukemia (ATL).
  • Previously, we detected OX40 expression in breast carcinoma cell lines and tissues.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibroadenoma / surgery. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Receptors, Progesterone / metabolism. Young Adult

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20634005.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / OX40 Ligand; 0 / Receptors, OX40; 0 / Receptors, Progesterone; 0 / TNFRSF4 protein, human; 0 / TNFSF4 protein, human
  •  go-up   go-down


71. Zhang Z, Zhang M, Garmestani K, Talanov VS, Plascjak PS, Beck B, Goldman C, Brechbiel MW, Waldmann TA: Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood; 2006 Aug 1;108(3):1007-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
  • Adult T-cell leukemia (ATL) consists of an overabundance of T cells, which express CD25.
  • Therapeutic efficacy of astatine-211 ((211)At)-labeled murine monoclonal antibody 7G7/B6 alone and in combination with daclizumab was evaluated in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice given injections of MET-1 human T-cell leukemia cells.
  • Either a single dose of 12 microCi (0.444 MBq) (211)At-7G7/B6 per mouse given intravenously or receptor-saturating doses of daclizumab given at 100 microg weekly for 4 weeks intravenously inhibited tumor growth as monitored by serum levels of human beta-2 microglobulin (beta(2)mu) and by prolonged survival of leukemia-bearing mice compared with the control groups (P < .001).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14 [11053100.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] Nucl Med Biol. 2001 Oct;28(7):845-56 [11578907.001]
  • [Cites] J Clin Microbiol. 1988 Oct;26(10):2127-31 [3053764.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1377-87 [2470706.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Lancet. 1995 Aug 5;346(8971):336-40 [7623531.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2535-43 [11588052.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1083-6 [11861386.001]
  • [Cites] Blood. 2002 Jul 1;100(1):208-16 [12070029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1891-5 [12569172.001]
  • [Cites] Blood. 2003 Jul 1;102(1):284-8 [12649132.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] Nucl Med Biol. 2004 Apr;31(3):357-64 [15028248.001]
  • [Cites] J Immunol. 1981 Apr;126(4):1393-7 [6970774.001]
  • [Cites] J Clin Invest. 1984 Jun;73(6):1711-8 [6327770.001]
  • [Cites] Hybridoma. 1985 Summer;4(2):91-102 [2408992.001]
  • [Cites] J Clin Invest. 1985 Aug;76(2):446-53 [2993359.001]
  • [Cites] Int J Rad Appl Instrum A. 1986;37(8):789-98 [3021680.001]
  • [Cites] Science. 1988 May 20;240(4855):1024-6 [2897133.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1383-400 [8648397.001]
  • [Cites] Phys Med Biol. 1996 Oct;41(10):1915-31 [8912371.001]
  • [Cites] Nucl Med Biol. 1998 Feb;25(2):89-93 [9468021.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):457-70 [9816191.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96 [15640792.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S [15653670.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1231-6 [15383455.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6977-84 [11156399.001]
  • (PMID = 16569769.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Epitopes; 0 / Immunoglobulin G; 0 / Receptors, Interleukin-2; CUJ2MVI71Y / daclizumab; XI595HAL7H / Astatine
  • [Other-IDs] NLM/ PMC1895861
  •  go-up   go-down


72. Grassmann R, Aboud M, Jeang KT: Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene; 2005 Sep 5;24(39):5976-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HTLV Tax protein is crucial for viral replication and for initiating malignant transformation leading to the development of adult T-cell leukemia.
  • Tax also stimulates cell growth by direct binding to cyclin-dependent kinase holenzymes and/or inactivating tumor suppressors (e.g. p53, DLG).
  • [MeSH-major] Cell Transformation, Neoplastic. Gene Products, tax / genetics. Human T-lymphotropic virus 1 / physiology
  • [MeSH-minor] Animals. Cytokines / genetics. DNA Damage. Humans. Mutation. Promoter Regions, Genetic. Receptors, Cell Surface / genetics. Signal Transduction. T-Lymphocytes / virology. Transcriptional Activation. Virus Replication

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155604.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Gene Products, tax; 0 / Receptors, Cell Surface
  • [Number-of-references] 158
  •  go-up   go-down


73. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW: FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res; 2008 Nov;32(11):1751-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
  • Engineered FBXW7 null cells display cell cycle and chromosome stability defects.
  • Mutations of FBXW7 have been found in human colorectal, ovarian, endometrial tumors and T-cell acute lymphocytic leukemias.
  • Prompted by these findings we have examined acute myeloid leukemia, non-Hodgkin's lymphoma, T-cell acute lymphocytic leukemia, B-cell acute lymphocytic leukemia and adult T-cell leukemia DNA for mutations of the FBXW7 gene.
  • As expected, mutations were found in T-cell acute lymphocytic leukemias.
  • However mutations of FBXW7 were also found in four of 118 B-cell acute lymphocytic leukemias and one of 24 adult T-cell leukemia samples.
  • These observations suggest that disruption of FBXW7 has a role in several forms of lymphocytic leukemias and not exclusively T-cell acute lymphocytic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Mutation / genetics. Ubiquitin-Protein Ligases / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485478.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


74. Pumfery A, de la Fuente C, Kashanchi F: HTLV-1 Tax: centrosome amplification and cancer. Retrovirology; 2006 Aug 09;3:50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During interphase, each cell contains a single centrosome that acts as a microtubule organizing center for cellular functions in interphase and in mitosis.
  • Centrosome amplification during the S phase of the cell cycle is a tightly regulated process to ensure that each daughter cell receives the proper complement of the genome.
  • The controls that ensure that centrosomes are duplicated exactly once in the cell cycle are not well understood.
  • These phenotypes are also observed in cancers induced by viruses, including adult T cell lymphoma which is caused by the human T cell lymphotrophic virus Type 1 (HTLV-1).
  • A recent paper in Nature Cell Biology by Ching et al. has shed some new light into how Tax may be inducing centrosome abnormalities.
  • Lastly, additional work on Tax1BP2 will also provide insight into how the cell suppresses centrosome re-duplication during the cell cycle and the role that Tax1BP2 plays in this important cellular pathway.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1999 Dec;73(12):9917-27 [10559304.001]
  • [Cites] Cancer Sci. 2006 Sep;97(9):836-41 [16805820.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):837-46 [11076968.001]
  • [Cites] Genes Dev. 2001 May 15;15(10):1167-81 [11358861.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22797-803 [11287420.001]
  • [Cites] Curr Biol. 2001 Sep 4;11(17):R698-701 [11553343.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3327-38 [11971966.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):378-85 [11992406.001]
  • [Cites] J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [12145525.001]
  • [Cites] Oncogene. 2002 Sep 9;21(40):6222-7 [12214252.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]
  • [Cites] Mutagenesis. 2003 May;18(3):221-33 [12714687.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):539-44 [12766773.001]
  • [Cites] Biochemistry. 2003 Jun 10;42(22):6921-8 [12779347.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):1993-2004 [12802070.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2003;13(1):9-23 [12839094.001]
  • [Cites] J Cell Sci. 2003 Aug 15;116(Pt 16):3399-411 [12840069.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5282-92 [12861014.001]
  • [Cites] Mol Cancer Res. 2004 Mar;2(3):159-69 [15037655.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4064-8 [15205312.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] DNA Cell Biol. 2004 Aug;23(8):475-89 [15307950.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2347-72 [15353292.001]
  • [Cites] Virology. 1993 Mar;193(1):456-9 [8438579.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1645-52 [8622884.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3620-32 [9584203.001]
  • [Cites] J Virol. 1998 Nov;72(11):8852-60 [9765430.001]
  • [Cites] J Cell Sci. 1999 Jul;112 ( Pt 14):2453-61 [10381400.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:919-30 [15569630.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):525-40 [15580311.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):626-32 [15908946.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):375-83 [15996491.001]
  • [Cites] Retrovirology. 2004;1:6 [15169570.001]
  • [Cites] Retrovirology. 2005;2:45 [16014171.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6719-28 [16007163.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:411-34 [16212501.001]
  • [Cites] Retrovirology. 2005;2:54 [16164752.001]
  • [Cites] Cancer Lett. 2005 Dec 8;230(1):6-19 [16253756.001]
  • [Cites] Trends Cell Biol. 2005 Nov;15(11):589-98 [16214339.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18974-9 [16365316.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):673-81 [16308315.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):717-24 [16767081.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32906-10 [10969065.001]
  • (PMID = 16899128.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI44357; United States / NIAID NIH HHS / AI / R01 AI043894; United States / PHS HHS / / 13969; United States / NIAID NIH HHS / AI / AI43894; United States / NIAID NIH HHS / AI / R29 AI044357
  • [Publication-type] Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / VAC14 protein, human
  • [Other-IDs] NLM/ PMC1555608
  •  go-up   go-down


75. Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E, Ravindranath Y, Camitta B: Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. J Pediatr Hematol Oncol; 2008 May;30(5):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
  • At concentrations >0.1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro.
  • This study of children with refractory acute leukemia was designed to take advantage of this biochemical modulation.
  • Thirty-three children [26 acute lymphocytic leukemia (ALL), 7 acute nonlymphocytic leukemia] were treated; 29 received at least 1 full course.
  • [MeSH-major] Cytarabine / toxicity. Hydroxyurea / toxicity. Leukemia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infection / epidemiology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality. Liver / drug effects. Liver / pathology. Skin / drug effects. Skin / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458568.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ NIHMS721202; NLM/ PMC4601800
  •  go-up   go-down


76. Miura H, Maeda M, Yamamoto N, Yamaoka S: Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells. Exp Cell Res; 2005 Aug 1;308(1):29-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells.
  • We have recently shown constitutive IkappaB kinase (IKK) activation and aberrant p52 expression in adult T cell leukemia (ATL) cells that do not express human T cell leukemia virus type I (HTLV-I) Tax, but the mechanism of IKK activation in these cells has remained unknown.
  • [MeSH-major] Cell Transformation, Viral / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Arsenites / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Cycloheximide / antagonists & inhibitors. Cycloheximide / pharmacology. Enzyme Inhibitors / pharmacology. Human T-lymphotropic virus 1 / physiology. Humans. I-kappa B Kinase. Leupeptins / pharmacology. Proteasome Endopeptidase Complex / metabolism. Protein Synthesis Inhibitors / pharmacology. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism

  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878527.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / Enzyme Inhibitors; 0 / Leupeptins; 0 / Protein Synthesis Inhibitors; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 98600C0908 / Cycloheximide; EC 2.7.1.- / IKBKE protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.10 / CHUK protein, human; EC 2.7.11.10 / I-kappa B Kinase; EC 2.7.11.10 / IKBKB protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex; N5509X556J / arsenite
  •  go-up   go-down


77. Tsuji T, Sheehy N, Gautier VW, Hayakawa H, Sawa H, Hall WW: The nuclear import of the human T lymphotropic virus type I (HTLV-1) tax protein is carrier- and energy-independent. J Biol Chem; 2007 May 4;282(18):13875-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HTLV-1 is the etiologic agent of the adult T cell leukemialymphoma (ATLL).
  • [MeSH-major] Cell Transformation, Viral. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Nuclear Pore / metabolism
  • [MeSH-minor] Active Transport, Cell Nucleus / genetics. Animals. COS Cells. Cercopithecus aethiops. Gene Expression Regulation, Leukemic / genetics. Gene Expression Regulation, Viral / genetics. HeLa Cells. Humans. Mutation. Nuclear Pore Complex Proteins / genetics. Nuclear Pore Complex Proteins / metabolism. Protein Binding / genetics. Transcription Factor RelA / genetics. Transcription Factor RelA / metabolism. beta Karyopherins / genetics. beta Karyopherins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344183.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Nuclear Pore Complex Proteins; 0 / Transcription Factor RelA; 0 / beta Karyopherins
  •  go-up   go-down


78. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foà R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood; 2006 Jan 15;107(2):473-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol.
  • Between 1996 and 2000, 90 newly diagnosed adult patients with T-acute lymphoblastic leukemia (T-ALL) were registered in the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acuta Limfoide (LAL) 0496 protocol.
  • An extensive biologic workup of adult T-ALL cases at presentation is recommended in order to design tailored therapeutic strategies aimed at improving CR rates.
  • [MeSH-major] Chromosome Aberrations. Leukemia-Lymphoma, Adult T-Cell. Oncogene Proteins, Fusion / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Adolescent. Adult. Cytogenetic Analysis. Drug Resistance, Multiple. Female. Humans. Immunophenotyping. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Prognosis. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179376.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / P-Glycoprotein
  •  go-up   go-down


79. Takayanagi R, Ohashi T, Yamashita E, Kurosaki Y, Tanaka K, Hakata Y, Komoda Y, Ikeda S, Tsunetsugu-Yokota Y, Tanaka Y, Shida H: Enhanced replication of human T-cell leukemia virus type 1 in T cells from transgenic rats expressing human CRM1 that is regulated in a natural manner. J Virol; 2007 Jun;81(11):5908-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced replication of human T-cell leukemia virus type 1 in T cells from transgenic rats expressing human CRM1 that is regulated in a natural manner.
  • Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia (ATL).
  • HTLV-1-infected T-cell lines derived from these Tg rats produced 100- to 10,000-fold more HTLV-1 than did T cells from wild-type rats, and the absolute levels of HTLV-1 were similar to those produced by human T cells.
  • [MeSH-major] Animals, Genetically Modified. Gene Expression Regulation, Neoplastic / physiology. Human T-lymphotropic virus 1 / physiology. Karyopherins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / virology. Receptors, Cytoplasmic and Nuclear / genetics. T-Lymphocyte Subsets / virology. Virus Replication / physiology
  • [MeSH-minor] Animals. Cell Line, Transformed. Cells, Cultured. Disease Models, Animal. Humans. Rats

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 1990;8:139-67 [2188661.001]
  • [Cites] Lancet. 1990 Dec 1;336(8727):1345-7 [1978165.001]
  • [Cites] Int J Cancer. 1991 Feb 20;47(4):491-5 [1995478.001]
  • [Cites] Int J Cancer. 1991 Jun 19;48(4):623-30 [1710610.001]
  • [Cites] Science. 1991 Jul 19;253(5017):317-20 [1857968.001]
  • [Cites] Curr Top Microbiol Immunol. 1995;193:79-89 [7648879.001]
  • [Cites] J Biol Chem. 1995 Nov 17;270(46):27489-94 [7499206.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):696-710 [8600320.001]
  • [Cites] Mol Cell Biol. 1996 Aug;16(8):4207-14 [8754820.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):5147-55 [8756672.001]
  • [Cites] Science. 1996 Nov 8;274(5289):985-9 [8875941.001]
  • [Cites] EMBO J. 1997 Feb 17;16(4):807-16 [9049309.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1041-50 [9323132.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1051-60 [9323133.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6437-47 [9343406.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1295-300 [9360927.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29742-51 [9368044.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7 [9371822.001]
  • [Cites] J Virol. 1998 May;72(5):3952-7 [9557681.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3101-11 [9606192.001]
  • [Cites] J Virol. 1998 Aug;72(8):6602-7 [9658105.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73 [9671771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14739-44 [9843959.001]
  • [Cites] J Virol. 1999 Jul;73(7):6031-40 [10364355.001]
  • [Cites] J Virol. 1999 Aug;73(8):6436-43 [10400737.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):257-67 [15551352.001]
  • [Cites] Microbes Infect. 2006 Mar;8(3):851-9 [16504563.001]
  • [Cites] Exp Cell Res. 2000 Jan 10;254(1):64-71 [10623466.001]
  • [Cites] J Cell Sci. 2000 Feb;113 ( Pt 3):451-9 [10639332.001]
  • [Cites] J Virol. 2000 Oct;74(20):9610-6 [11000233.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):981-9 [1402668.001]
  • [Cites] J Virol. 1992 Nov;66(11):6686-94 [1404610.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):582-8 [8514449.001]
  • [Cites] Lab Invest. 1993 Sep;69(3):336-9 [8377474.001]
  • [Cites] J Virol. 1994 Nov;68(11):7221-6 [7933104.001]
  • [Cites] Nat Med. 2001 Apr;7(4):459-64 [11283673.001]
  • [Cites] J Cell Biol. 2001 Jun 25;153(7):1391-402 [11425870.001]
  • [Cites] J Virol. 2001 Dec;75(23):11515-25 [11689633.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1895-901 [11729309.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1775-83 [11734593.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47958-65 [11602610.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17385-8 [11932251.001]
  • [Cites] Immunol Res. 2002;25(3):229-45 [12018462.001]
  • [Cites] J Virol. 2002 Aug;76(16):8079-89 [12134013.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8751-61 [14612415.001]
  • [Cites] J Virol. 2004 Apr;78(8):3827-36 [15047798.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] J Exp Med. 1984 Apr 1;159(4):1105-16 [6323614.001]
  • [Cites] Nature. 1984 Apr 19-25;308(5961):693-8 [6232463.001]
  • [Cites] J Immunol. 1984 Aug;133(2):1037-41 [6203964.001]
  • [Cites] Int J Cancer. 1984 Oct 15;34(4):513-7 [6092283.001]
  • [Cites] Jpn J Cancer Res. 1985 Feb;76(2):86-94 [2984072.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Int J Cancer. 1986 Dec 15;38(6):867-75 [2878891.001]
  • [Cites] Lancet. 1987 May 9;1(8541):1085-6 [2883415.001]
  • [Cites] Science. 1987 May 29;236(4805):1103-6 [2883731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jun;84(11):3653-7 [3035544.001]
  • [Cites] Int J Cancer. 1987 Sep 15;40(3):403-7 [2887518.001]
  • [Cites] EMBO J. 1988 Feb;7(2):519-23 [2835230.001]
  • [Cites] Nature. 1988 Oct 20;335(6192):738-40 [3262832.001]
  • [Cites] Lancet. 1989 Feb 25;1(8635):441 [2563817.001]
  • [Cites] J Cell Biol. 1989 Apr;108(4):1195-207 [2647765.001]
  • [Cites] J Virol. 1990 Mar;64(3):1278-82 [2304144.001]
  • [Cites] EMBO J. 1990 May;9(5):1551-60 [2184033.001]
  • [Cites] J Cell Biol. 2000 Oct 2;151(1):1-14 [11018049.001]
  • [Cites] Cytometry. 2000 Dec 1;41(4):261-70 [11084611.001]
  • (PMID = 17360758.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Karyopherins; 0 / Receptors, Cytoplasmic and Nuclear; 0 / exportin 1 protein
  • [Other-IDs] NLM/ PMC1900248
  •  go-up   go-down


80. Silverman LR, Phipps AJ, Montgomery A, Fernandez S, Tsukahara T, Ratner L, Lairmore MD: In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations. Blood; 2005 Nov 15;106(10):3602-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell lymphoma/leukemia (ATL).
  • Herein, we examined the effects of these Env mutants in rabbits inoculated with HTLV-1 immortalized ACH.75, ACH.95, or ACH.195 cell lines (expressing full-length molecular clones with the SU mutations) or the ACH.1 cell line (expressing wild-type SU).
  • However, peripheral-blood mononuclear cell (PBMC) proviral loads did not correlate with antibody responses.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):74-83 [12925959.001]
  • [Cites] Virology. 1984 Jul 30;136(2):338-47 [6087548.001]
  • [Cites] Mol Biol Med. 1988 Feb;5(1):29-42 [2897612.001]
  • [Cites] J Gen Virol. 1988 Jul;69 ( Pt 7):1695-710 [2899128.001]
  • [Cites] J Immunol. 1989 Feb 1;142(3):971-8 [2563272.001]
  • [Cites] J Virol. 1990 Mar;64(3):1278-82 [2304144.001]
  • [Cites] J Clin Microbiol. 1990 Apr;28(4):646-50 [2185257.001]
  • [Cites] EMBO J. 1990 Dec;9(13):4243-8 [2124968.001]
  • [Cites] Virology. 1991 May;182(1):413-9 [2024477.001]
  • [Cites] J Immunol. 1991 Jul 1;147(1):354-60 [1711082.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2082-8 [1680498.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] N Engl J Med. 1992 Feb 6;326(6):375-80 [1729620.001]
  • [Cites] J Immunol. 1992 Aug 1;149(3):940-8 [1378869.001]
  • [Cites] J Immunol. 1993 Jul 15;151(2):1013-24 [7687611.001]
  • [Cites] J Virol. 1994 Jun;68(6):3544-9 [8189493.001]
  • [Cites] Baillieres Clin Haematol. 1993 Dec;6(4):899-915 [8038496.001]
  • [Cites] J Virol. 1994 Oct;68(10):6323-31 [8083972.001]
  • [Cites] Virology. 1994 Nov 1;204(2):656-64 [7941334.001]
  • [Cites] J Virol. 1996 Oct;70(10):7241-6 [8794375.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S85-91 [8797709.001]
  • [Cites] J Virol. 1997 Jan;71(1):259-66 [8985345.001]
  • [Cites] J Med Virol. 1997 Jan;51(1):25-31 [8986945.001]
  • [Cites] J Infect Dis. 1997 Mar;175(3):716-9 [9041352.001]
  • [Cites] Am J Trop Med Hyg. 1997 Aug;57(2):142-8 [9288805.001]
  • [Cites] J Virol. 1997 Oct;71(10):7180-6 [9311790.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4701-7 [9616168.001]
  • [Cites] J Neurol Sci. 1998 Jul 15;159(1):67-72 [9700706.001]
  • [Cites] J Neurovirol. 1998 Dec;4(6):586-93 [10065900.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3963-9 [12907436.001]
  • [Cites] Cell. 2003 Nov 14;115(4):449-59 [14622599.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 [15129647.001]
  • [Cites] J Virol. 1999 Nov;73(11):9369-76 [10516045.001]
  • [Cites] Proc Assoc Am Physicians. 1996 Nov;108(6):444-8 [8956367.001]
  • [Cites] Transfusion. 1999 Nov-Dec;39(11-12):1185-93 [10604244.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 1;16(7):665-75 [10791877.001]
  • [Cites] J Natl Cancer Inst. 2001 Mar 7;93(5):367-77 [11238698.001]
  • [Cites] Virus Res. 2001 Oct 30;78(1-2):5-16 [11520576.001]
  • [Cites] J Virol. 2001 Oct;75(19):9553-9 [11533220.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Clin Lab Haematol. 2003 Apr;25(2):111-7 [12641615.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3856-60 [6328528.001]
  • (PMID = 16046523.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100730-02; United States / NCI NIH HHS / CA / CA-63417; United States / NCI NIH HHS / CA / CA09338; United States / NCI NIH HHS / CA / CA70529
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Gene Products, env; 0 / Gene Products, gag
  • [Other-IDs] NLM/ PMC1895059
  •  go-up   go-down


81. Shimauchi T, Kabashima K, Tokura Y: Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Sci; 2008 Jan;99(1):98-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells.
  • Adult T cell leukemia/lymphoma (ATL) cells share the CD4(+)CD25(+) phenotype with regulatory T (Treg) cells.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, Differentiation / biosynthesis. CD8-Positive T-Lymphocytes / immunology. Forkhead Transcription Factors / biosynthesis. Leukemia-Lymphoma, Adult T-Cell / immunology. Skin Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antigens, CD28 / immunology. Antigens, CD3 / immunology. CTLA-4 Antigen. Female. Humans. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970785.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, CD3; 0 / Antigens, Differentiation; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


82. Uchimaru K, Nakamura Y, Tojo A, Watanabe T, Yamaguchi K: Factors predisposing to HTLV-1 infection in residents of the greater Tokyo area. Int J Hematol; 2008 Dec;88(5):565-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent for adult T-cell leukemia.
  • [MeSH-major] Emigration and Immigration. Endemic Diseases. HTLV-I Infections / epidemiology. Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Causality. Female. Humans. Male. Middle Aged. Prevalence. Tokyo

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2002 Mar 1;185(5):691-5 [11865428.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Jpn J Cancer Res. 1985 Dec;76(12):1147-53 [3005206.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6 [8680890.001]
  • [Cites] Int J Hematol. 2003 Feb;77(2):164-70 [12627852.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] J Acquir Immune Defic Syndr. 1992;5(5):533-4 [1560354.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Int J Cancer. 1984 Jun 15;33(6):717-20 [6329964.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):128-41 [2891797.001]
  • [Cites] J Infect Dis. 1993 Jan;167(1):57-65 [8418183.001]
  • [Cites] Jpn J Cancer Res. 1992 Mar;83(3):236-9 [1582883.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5458-64 [17968021.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Leukemia. 2005 May;19(5):829-34 [15744352.001]
  • (PMID = 19034610.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


83. Asnafi V, Buzyn A, Thomas X, Huguet F, Vey N, Boiron JM, Reman O, Cayuela JM, Lheritier V, Vernant JP, Fiere D, Macintyre E, Dombret H: Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood; 2005 Apr 15;105(8):3072-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study.
  • Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucemies Aigues Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course.
  • Representative patients with T-ALL (91 patients) were classified into surface T-cell receptor (TCR)-expressing T-ALL patients (TCRalphabeta+ or TCRgammadelta+), pre-alphabeta T-ALL patients (cTCRbeta+, TCR-), and immature (IM) cTCRbeta-, TCR- T-ALL patients; 81 patients underwent genotyping for SIL-TAL1, CALM-AF10, HOX11, and HOX11L2.
  • Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cytarabine / administration & dosage. Genotype. Humans. Immunophenotyping. Incidence. Middle Aged. Mitoxantrone / administration & dosage. Prospective Studies. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637138.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Receptors, Antigen, T-Cell; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


84. Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, Tsuruda K, Tsukasaki K, Tomonaga M, Hirakata Y, Kamihira S: Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett; 2006 Mar 28;234(2):249-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma.
  • Based on statistical analysis of its age-dependent occurrence, a multi-step carcinogenesis model has been proposed for Adult T-cell Leukemia/Lymphoma (ATLL).
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosome Aberrations. Genes, p16. Genes, p53. Leukemia, T-Cell / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Polymorphism, Single-Stranded Conformational. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896902.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Peloponese JM Jr, Haller K, Miyazato A, Jeang KT: Abnormal centrosome amplification in cells through the targeting of Ran-binding protein-1 by the human T cell leukemia virus type-1 Tax oncoprotein. Proc Natl Acad Sci U S A; 2005 Dec 27;102(52):18974-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal centrosome amplification in cells through the targeting of Ran-binding protein-1 by the human T cell leukemia virus type-1 Tax oncoprotein.
  • Human T cell leukemia virus type-1 (HTLV-1) is an oncogenic retrovirus etiologically causal of adult T cell leukemia.
  • The virus encodes a Tax oncoprotein that functions in transcriptional regulation, cell cycle control, and transformation.
  • Because adult T cell leukemia like many other human cancers is a disease of genomic instability with frequent gains and losses of chromosomes, to understand this disease it is important to comprehend how HTLV-1 engenders aneuploidy in host cells.
  • In this regard, loss of cell cycle checkpoints permits tolerance of aneuploidy but does not explain how aneuploidy is created.
  • We show here that HTLV-1 Tax causes abnormal centrosome fragmentation in the mitotic phase of the cell cycle.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Mar;74(6):2655-62 [10684280.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Prog Cell Cycle Res. 2000;4:157-62 [10740823.001]
  • [Cites] Cell Growth Differ. 2000 Aug;11(8):455-65 [10965850.001]
  • [Cites] Curr Top Dev Biol. 2000;49:1-25 [11005012.001]
  • [Cites] J Virol. 2001 Mar;75(5):2161-73 [11160720.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2212-9 [11280789.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12(2-3):207-17 [11325603.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4484-96 [11494144.001]
  • [Cites] J Cell Sci. 2001 Sep;114(Pt 18):3233-41 [11591812.001]
  • [Cites] Dis Markers. 2001;17(3):129-37 [11790876.001]
  • [Cites] Onkologie. 2001 Dec;24(6):538-44 [11799308.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5187-93 [11729202.001]
  • [Cites] J Virol. 2002 Apr;76(8):4022-33 [11907241.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3327-38 [11971966.001]
  • [Cites] Leukemia. 2002 May;16(5):767-75 [11986936.001]
  • [Cites] FEBS Lett. 2002 Jun 19;521(1-3):9-13 [12067716.001]
  • [Cites] J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [12145525.001]
  • [Cites] Curr Biol. 2002 Jul 23;12(14):R502-8 [12176353.001]
  • [Cites] Oncogene. 2002 Sep 9;21(40):6146-53 [12214243.001]
  • [Cites] Oncogene. 2002 Sep 9;21(40):6234-40 [12214254.001]
  • [Cites] Oncogene. 2002 Sep 9;21(40):6241-8 [12214255.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Virology. 2003 Jan 20;305(2):229-39 [12573569.001]
  • [Cites] J Cell Sci. 2003 Aug 15;116(Pt 16):3399-411 [12840069.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37736-44 [12842897.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):346-52 [14506732.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 17;95(24):1846-59 [14679154.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] DNA Cell Biol. 2004 Aug;23(8):475-89 [15307950.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:3374-83 [15353364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] FASEB J. 1990 Feb 1;4(2):169-75 [2404818.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] Sci Am. 1993 Jun;268(6):62-8 [8516675.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] J Cell Sci. 2000 Apr;113 ( Pt 7):1111-8 [10704362.001]
  • [Cites] Nature. 1993 Oct 14;365(6447):661-3 [8413630.001]
  • [Cites] J Virol. 2000 Mar;74(5):2351-64 [10666266.001]
  • [Cites] Cell Growth Differ. 1995 Oct;6(10):1213-24 [8845298.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1607-14 [8612584.001]
  • [Cites] Genes Dev. 1996 Oct 15;10(20):2621-31 [8895663.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3974-85 [9731511.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Methods Cell Biol. 1999;58:223-38 [9891384.001]
  • [Cites] Curr Biol. 1999 Jun 17;9(12):R449-52 [10375518.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 7;262(3):571-4 [10471364.001]
  • [Cites] J Cell Biol. 1999 Sep 20;146(6):1205-10 [10491385.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):338-41 [15549096.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Jul;9(3):275-83 [15557800.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:728-42 [15569613.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):1 [15613282.001]
  • [Cites] Retrovirology. 2004;1:6 [15169570.001]
  • [Cites] Retrovirology. 2005;2:27 [15854229.001]
  • [ErratumIn] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1153
  • (PMID = 16365316.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Nuclear Proteins; 0 / ran-binding protein 1; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.5.2 / ran GTP-Binding Protein
  • [Other-IDs] NLM/ PMC1323167
  •  go-up   go-down


86. Uozumi K: Treatment of adult T-cell leukemia. J Clin Exp Hematop; 2010;50(1):9-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult T-cell leukemia.
  • Adult T-cell Leukemia (ATL) is an aggressive malignant disease of CD4+ T-cells associated with human T-cell leukemia virus type I (HTLV-I).
  • Treatment of the aggressive forms (acute and lymphoma types) of ATL remains inadequate, as most ATL patients receive conventional chemotherapy without stem cell rescue.
  • Improved outcome after allogeneic stem cell transplantation (allo-SCT), despite a high incidence of graft-versus-host disease, has been reported.
  • Recently, reduced-intensity conditioning stem cell transplantation was also reported to be effective for ATL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Graft vs Host Disease. Human T-lymphotropic virus 1. Humans. Remission Induction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505272.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


87. Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O: Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol; 2008 Dec 10;26(35):5728-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
  • PURPOSE: Acute graft-versus-host disease (GVHD) causes substantial morbidity and mortality after human leukocyte antigen (HLA)-identical sibling transplants.
  • No large registry studies of acute GVHD risk factors have been reported in two decades.
  • PATIENTS AND METHODS: Acute GVHD risk factors were analyzed in 1,960 adults after HLA-identical sibling myeloablative transplant for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or chronic myeloid leukemia (CML) reported by 226 centers worldwide to the Center for International Blood and Marrow Transplant Research from 1995 to 2002.
  • Outcome was measured as time from transplant to onset of grade 2 to 4 acute GVHD, with death without acute GVHD as a competing risk.
  • RESULTS: Cumulative incidence of grade 2 to 4 acute GVHD was 35% (95% CI, 33% to 37%).
  • In multivariable analyses, factors significantly associated with grade 2 to 4 acute GVHD were cyclophosphamide + total-body irradiation versus busulfan + cyclophosphamide (relative risk [RR] = 1.4; P < .0001), blood cell versus bone marrow grafts in patients age 18 to 39 years (RR = 1.43; P = .0023), recipient age 40 and older versus age 18 to 39 years receiving bone marrow grafts (RR = 1.44; P = .0005), CML versus AML/ALL (RR = 1.35; P = .0003), white/Black versus Asian/Hispanic race (RR = 1.54; P = .0003), Karnofsky performance score less than 90 versus 90 to 100 (RR = 1.27; P = .014), and recipient/donor cytomegalovirus-seronegative versus either positive (RR = 1.20; P = .04).
  • Stratification by disease showed the same significant predictors of grade 2 to 4 acute GVHD for CML; however, KPS and cytomegalovirus serostatus were not significant predictors for AML/ALL.
  • CONCLUSION: This analysis confirmed several previously reported risk factors for grade 2 to 4 acute GVHD.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5695-702 [17116940.001]
  • [Cites] Ann Transplant. 2006;11(1):16-23 [17025025.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3702-9 [10845900.001]
  • [Cites] N Engl J Med. 1983 Feb 10;308(6):302-7 [6337323.001]
  • [Cites] Br J Haematol. 1987 Dec;67(4):397-406 [3322360.001]
  • [Cites] N Engl J Med. 1988 Jul 14;319(2):65-70 [3288872.001]
  • [Cites] Blood. 1990 Feb 15;75(4):1011-6 [2405918.001]
  • [Cites] Bone Marrow Transplant. 1990 Jun;5(6):413-8 [2164434.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):705-12 [2167452.001]
  • [Cites] Hum Immunol. 1990 Oct;29(2):79-91 [2249952.001]
  • [Cites] Transplantation. 1991 Jun;51(6):1197-203 [2048196.001]
  • [Cites] Bone Marrow Transplant. 1991 Jun;7(6):461-5 [1873593.001]
  • [Cites] Bone Marrow Transplant. 1991 Jul;8(1):13-7 [1912953.001]
  • [Cites] Blood. 1992 May 15;79(10):2578-82 [1586710.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1838-45 [1391947.001]
  • [Cites] Blood. 1994 May 1;83(9):2723-30 [8167351.001]
  • [Cites] Blood. 1994 Sep 15;84(6):2036-43 [8081005.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2263-8 [7718899.001]
  • [Cites] Bone Marrow Transplant. 1995 May;15(5):663-8 [7670393.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Bone Marrow Transplant. 1995 Dec;16(6):747-53 [8750264.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(2):145-50 [10197799.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1408-16 [15486071.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] Bone Marrow Transplant. 2006 Apr;37(7):635-40 [16474409.001]
  • [Cites] Blood. 2000 May 1;95(9):2754-9 [10779417.001]
  • (PMID = 18981462.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ PMC2645611
  •  go-up   go-down


88. Manola KN, Sambani C, Karakasis D, Kalliakosta G, Harhalakis N, Papaioannou M: Leukemias associated with Turner syndrome: report of three cases and review of the literature. Leuk Res; 2008 Mar;32(3):481-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of leukemia associated with Turner syndrome (TS) are rare.
  • Here we report three TS patients with leukemia including one case of T-large granular lymphocyte leukemia (T-LGL), one rare case of coexistence of chronic lymphocytic leukemia (CLL) and idiopathic myelofibrosis (IMF) and one case of a patient with AML-M2 who received autologous stem cell transplantation (SCT).
  • T-LGL and coexistence of CLL and IMF associated with TS are reported for the first time while the last case represents the first report of SCT in a leukemia patient with TS.
  • Our cases and the limited data of previously reported leukemia patients with TS suggest that TS is not associated with a specific type of leukemia and that presentation, clinical course and response to treatment are similar to that of the non-TS leukemia patients.
  • Interestingly, in the mosaic TS patients, the abnormal clones were restricted to the monosomic 45,X cells, indicating that the leukemic clones possibly originate from the monosomic cell line.
  • Even in cases with no additional chromosome abnormalities, the ratio of X/XX cells in bone marrow cells was significantly increased compared to that in constitutional karyotype, indicating that monosomic cells possibly provide a survival advantage for leukemia cells or that reduced programmed cell death may be responsible for the expansion of the monosomic cells.
  • [MeSH-major] Leukemia / complications. Turner Syndrome / complications
  • [MeSH-minor] Adult. Female. Humans. Leukemia, Large Granular Lymphocytic / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Myeloid, Acute / complications. Middle Aged. Monosomy. Treatment Outcome